NZ626187B2 - Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors - Google Patents
Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors Download PDFInfo
- Publication number
- NZ626187B2 NZ626187B2 NZ626187A NZ62618712A NZ626187B2 NZ 626187 B2 NZ626187 B2 NZ 626187B2 NZ 626187 A NZ626187 A NZ 626187A NZ 62618712 A NZ62618712 A NZ 62618712A NZ 626187 B2 NZ626187 B2 NZ 626187B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- tumor
- brain
- minicells
- drug
- cells
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims abstract description 131
- 208000003174 Brain Neoplasms Diseases 0.000 title claims abstract description 119
- 239000000203 mixture Substances 0.000 claims abstract description 63
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 45
- 102000004965 antibodies Human genes 0.000 claims abstract description 35
- 108090001123 antibodies Proteins 0.000 claims abstract description 35
- 210000004204 Blood Vessels Anatomy 0.000 claims abstract description 13
- 239000000427 antigen Substances 0.000 claims abstract description 11
- 102000038129 antigens Human genes 0.000 claims abstract description 11
- 108091007172 antigens Proteins 0.000 claims abstract description 11
- 238000004519 manufacturing process Methods 0.000 claims abstract description 5
- 229940079593 drugs Drugs 0.000 claims description 113
- 210000004027 cells Anatomy 0.000 claims description 111
- 206010028980 Neoplasm Diseases 0.000 claims description 73
- 230000027455 binding Effects 0.000 claims description 47
- 210000004881 tumor cells Anatomy 0.000 claims description 45
- 210000004556 Brain Anatomy 0.000 claims description 41
- 108020004707 nucleic acids Proteins 0.000 claims description 37
- 201000005216 brain cancer Diseases 0.000 claims description 36
- 150000007523 nucleic acids Chemical class 0.000 claims description 36
- 238000002512 chemotherapy Methods 0.000 claims description 34
- 201000011510 cancer Diseases 0.000 claims description 32
- 239000003446 ligand Substances 0.000 claims description 30
- 102000004169 proteins and genes Human genes 0.000 claims description 29
- 108090000623 proteins and genes Proteins 0.000 claims description 29
- 239000004055 small Interfering RNA Substances 0.000 claims description 28
- 229920001239 microRNA Polymers 0.000 claims description 22
- 102000005962 receptors Human genes 0.000 claims description 20
- 108020003175 receptors Proteins 0.000 claims description 20
- 108020004388 MicroRNAs Proteins 0.000 claims description 17
- 230000001580 bacterial Effects 0.000 claims description 17
- 239000002679 microRNA Substances 0.000 claims description 16
- 239000002158 endotoxin Substances 0.000 claims description 14
- 208000005017 Glioblastoma Diseases 0.000 claims description 12
- 206010059512 Apoptosis Diseases 0.000 claims description 7
- 108020004459 Small Interfering RNA Proteins 0.000 claims description 7
- 230000006907 apoptotic process Effects 0.000 claims description 7
- 206010003571 Astrocytoma Diseases 0.000 claims description 6
- 230000033115 angiogenesis Effects 0.000 claims description 6
- 230000004663 cell proliferation Effects 0.000 claims description 5
- 208000009798 Craniopharyngioma Diseases 0.000 claims description 4
- 230000025084 cell cycle arrest Effects 0.000 claims description 4
- 229920002033 ribozyme Polymers 0.000 claims description 4
- 229940006110 Gallium-67 Drugs 0.000 claims description 3
- 241000282619 Hylobates lar Species 0.000 claims description 3
- ZCYVEMRRCGMTRW-RNFDNDRNSA-N I-131 Chemical compound [131I] ZCYVEMRRCGMTRW-RNFDNDRNSA-N 0.000 claims description 3
- 231100000111 LD50 Toxicity 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 206010025310 Other lymphomas Diseases 0.000 claims description 3
- 208000007641 Pinealoma Diseases 0.000 claims description 3
- 229920001891 Small hairpin RNA Polymers 0.000 claims description 3
- 229940056501 Technetium 99m Drugs 0.000 claims description 3
- 229940106670 Xenon-133 Drugs 0.000 claims description 3
- 150000001720 carbohydrates Chemical class 0.000 claims description 3
- GYHNNYVSQQEPJS-OIOBTWANSA-N gallium-67 Chemical compound [67Ga] GYHNNYVSQQEPJS-OIOBTWANSA-N 0.000 claims description 3
- ZCYVEMRRCGMTRW-AHCXROLUSA-N iodine-123 Chemical compound [123I] ZCYVEMRRCGMTRW-AHCXROLUSA-N 0.000 claims description 3
- 201000010133 oligodendroglioma Diseases 0.000 claims description 3
- 229920000023 polynucleotide Polymers 0.000 claims description 3
- 239000002157 polynucleotide Substances 0.000 claims description 3
- IGLNJRXAVVLDKE-OIOBTWANSA-N rubidium-82 Chemical compound [82Rb] IGLNJRXAVVLDKE-OIOBTWANSA-N 0.000 claims description 3
- 239000002924 silencing RNA Substances 0.000 claims description 3
- GKLVYJBZJHMRIY-OUBTZVSYSA-N technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 claims description 3
- 229960001711 xenon (133Xe) gas Drugs 0.000 claims description 3
- FHNFHKCVQCLJFQ-NJFSPNSNSA-N xenon-133 Chemical compound [133Xe] FHNFHKCVQCLJFQ-NJFSPNSNSA-N 0.000 claims description 3
- YCKRFDGAMUMZLT-BJUDXGSMSA-N (18)F Chemical compound [18F] YCKRFDGAMUMZLT-BJUDXGSMSA-N 0.000 claims description 2
- 108020005544 Antisense RNA Proteins 0.000 claims description 2
- 108091007200 Long intergenic noncoding RNA Proteins 0.000 claims description 2
- 108009000215 Metastatic brain tumor Proteins 0.000 claims description 2
- 241000840267 Moma Species 0.000 claims description 2
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims description 2
- 229920002847 antisense RNA Polymers 0.000 claims description 2
- 239000003184 complementary RNA Substances 0.000 claims description 2
- 210000004602 germ cell Anatomy 0.000 claims description 2
- 102000006240 membrane receptors Human genes 0.000 claims description 2
- 108020004084 membrane receptors Proteins 0.000 claims description 2
- 230000000242 pagocytic Effects 0.000 claims description 2
- BKVIYDNLLOSFOA-OIOBTWANSA-N thallium-201 Chemical compound [201Tl] BKVIYDNLLOSFOA-OIOBTWANSA-N 0.000 claims description 2
- VWQVUPCCIRVNHF-OUBTZVSYSA-N yttrium-90 Chemical group [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 claims description 2
- 229940055742 Indium-111 Drugs 0.000 claims 1
- APFVFJFRJDLVQX-AHCXROLUSA-N indium-111 Chemical compound [111In] APFVFJFRJDLVQX-AHCXROLUSA-N 0.000 claims 1
- 230000000989 vascularization Effects 0.000 claims 1
- 210000001218 Blood-Brain Barrier Anatomy 0.000 description 60
- 241000282472 Canis lupus familiaris Species 0.000 description 52
- -1 fluorine-l 8 Chemical compound 0.000 description 34
- 239000003795 chemical substances by application Substances 0.000 description 28
- 235000018102 proteins Nutrition 0.000 description 26
- 241000282465 Canis Species 0.000 description 25
- 229920001985 Small interfering RNA Polymers 0.000 description 25
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 24
- 229960004679 Doxorubicin Drugs 0.000 description 22
- 238000002595 magnetic resonance imaging Methods 0.000 description 22
- 210000002966 Serum Anatomy 0.000 description 19
- 239000002105 nanoparticle Substances 0.000 description 19
- 150000003384 small molecules Chemical class 0.000 description 19
- 230000000694 effects Effects 0.000 description 17
- 230000002401 inhibitory effect Effects 0.000 description 17
- 108010045030 monoclonal antibodies Proteins 0.000 description 17
- 102000005614 monoclonal antibodies Human genes 0.000 description 17
- 230000001225 therapeutic Effects 0.000 description 17
- 210000001519 tissues Anatomy 0.000 description 17
- 230000014509 gene expression Effects 0.000 description 16
- 239000002245 particle Substances 0.000 description 16
- 230000004044 response Effects 0.000 description 16
- 206010006187 Breast cancer Diseases 0.000 description 15
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 14
- 239000002773 nucleotide Substances 0.000 description 13
- OLESAACUTLOWQZ-UHFFFAOYSA-L Carboplatin Chemical compound O=C1O[Pt]([N]([H])([H])[H])([N]([H])([H])[H])OC(=O)C11CCC1 OLESAACUTLOWQZ-UHFFFAOYSA-L 0.000 description 12
- 210000003169 Central Nervous System Anatomy 0.000 description 12
- SDUQYLNIPVEERB-QPPQHZFASA-N Gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 12
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 12
- 229960001592 Paclitaxel Drugs 0.000 description 12
- 125000003729 nucleotide group Chemical group 0.000 description 12
- 229930003347 taxol Natural products 0.000 description 12
- 229960004562 Carboplatin Drugs 0.000 description 11
- 206010059282 Metastases to central nervous system Diseases 0.000 description 11
- 239000003112 inhibitor Substances 0.000 description 11
- 239000012528 membrane Substances 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 238000002603 single-photon emission computed tomography Methods 0.000 description 11
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 10
- 210000004369 Blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 239000002609 media Substances 0.000 description 9
- 238000004806 packaging method and process Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 230000002588 toxic Effects 0.000 description 9
- 231100000331 toxic Toxicity 0.000 description 9
- 229940034982 ANTINEOPLASTIC AGENTS Drugs 0.000 description 8
- 210000000805 Cytoplasm Anatomy 0.000 description 8
- 206010059866 Drug resistance Diseases 0.000 description 8
- 210000002889 Endothelial Cells Anatomy 0.000 description 8
- 230000000259 anti-tumor Effects 0.000 description 8
- 238000001990 intravenous administration Methods 0.000 description 8
- 210000004962 mammalian cells Anatomy 0.000 description 8
- 230000004083 survival Effects 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 230000001988 toxicity Effects 0.000 description 8
- 231100000419 toxicity Toxicity 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 210000001736 Capillaries Anatomy 0.000 description 7
- 241000229754 Iva xanthiifolia Species 0.000 description 7
- 210000004185 Liver Anatomy 0.000 description 7
- 206010061289 Metastatic neoplasm Diseases 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 230000003211 malignant Effects 0.000 description 7
- 230000001394 metastastic Effects 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 229940020967 Gemzar Drugs 0.000 description 6
- 230000025458 RNA interference Effects 0.000 description 6
- 230000012202 endocytosis Effects 0.000 description 6
- 229960005277 gemcitabine Drugs 0.000 description 6
- 210000001539 phagocyte Anatomy 0.000 description 6
- 239000011148 porous material Substances 0.000 description 6
- 230000001105 regulatory Effects 0.000 description 6
- 230000002987 rna-interference Effects 0.000 description 6
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 6
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 description 6
- 206010009944 Colon cancer Diseases 0.000 description 5
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- 229960003048 Vinblastine Drugs 0.000 description 5
- HOFQVRTUGATRFI-XQKSVPLYSA-N Vinblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 HOFQVRTUGATRFI-XQKSVPLYSA-N 0.000 description 5
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 5
- 230000000903 blocking Effects 0.000 description 5
- 229960004316 cisplatin Drugs 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000002068 genetic Effects 0.000 description 5
- 230000002209 hydrophobic Effects 0.000 description 5
- 230000001965 increased Effects 0.000 description 5
- 230000003834 intracellular Effects 0.000 description 5
- 238000002372 labelling Methods 0.000 description 5
- 238000011068 load Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 4
- 208000002352 Blister Diseases 0.000 description 4
- 241000283707 Capra Species 0.000 description 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
- 229920002521 Macromolecule Polymers 0.000 description 4
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N Melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 4
- 108020004999 Messenger RNA Proteins 0.000 description 4
- 101710040537 TNF Proteins 0.000 description 4
- 108010010691 Trastuzumab Proteins 0.000 description 4
- 231100000494 adverse effect Toxicity 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 238000002296 dynamic light scattering Methods 0.000 description 4
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
- 238000005755 formation reaction Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 201000005202 lung cancer Diseases 0.000 description 4
- 230000001404 mediated Effects 0.000 description 4
- 229960001924 melphalan Drugs 0.000 description 4
- 229920002106 messenger RNA Polymers 0.000 description 4
- 230000002018 overexpression Effects 0.000 description 4
- 200000000025 progressive disease Diseases 0.000 description 4
- 238000011105 stabilization Methods 0.000 description 4
- 229960000575 trastuzumab Drugs 0.000 description 4
- COVZYZSDYWQREU-UHFFFAOYSA-N 1,4-Butanediol, dimethanesulfonate Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 3
- GHASVSINZRGABV-UHFFFAOYSA-N 5-flurouricil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 3
- 101700040074 ABCG2 Proteins 0.000 description 3
- 102100002706 ABCG2 Human genes 0.000 description 3
- 101710027066 ALB Proteins 0.000 description 3
- 101710034857 ATIC Proteins 0.000 description 3
- 235000014469 Bacillus subtilis Nutrition 0.000 description 3
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 3
- 206010010904 Convulsion Diseases 0.000 description 3
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytosar Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 3
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N Docetaxel Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 102000001301 EGF receptors Human genes 0.000 description 3
- 108060006698 EGF receptors Proteins 0.000 description 3
- 101700025368 ERBB2 Proteins 0.000 description 3
- 102100016662 ERBB2 Human genes 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 3
- 206010018338 Glioma Diseases 0.000 description 3
- UWKQSNNFCGGAFS-XIFFEERXSA-N Irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
- 108060004326 LDLR Proteins 0.000 description 3
- 210000003712 Lysosomes Anatomy 0.000 description 3
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229960000350 Mitotane Drugs 0.000 description 3
- 102000004855 Multi drug resistance-associated proteins Human genes 0.000 description 3
- 108090001099 Multi drug resistance-associated proteins Proteins 0.000 description 3
- 102000004233 Multidrug resistance protein 3 Human genes 0.000 description 3
- 108090000743 Multidrug resistance protein 3 Proteins 0.000 description 3
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Nitrumon Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 3
- 210000004940 Nucleus Anatomy 0.000 description 3
- 208000008443 Pancreatic Carcinoma Diseases 0.000 description 3
- 208000003991 Primitive Neuroectodermal Tumors Diseases 0.000 description 3
- CPTBDICYNRMXFX-UHFFFAOYSA-N Procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 3
- 102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 3
- 108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 3
- 101710023234 Segment 5 Proteins 0.000 description 3
- 206010039911 Seizure Diseases 0.000 description 3
- 102000018075 Subfamily B ATP Binding Cassette Transporter Human genes 0.000 description 3
- 229960001603 Tamoxifen Drugs 0.000 description 3
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 3
- 229960005454 Thioguanine Drugs 0.000 description 3
- 102000005497 Thymidylate Synthase Human genes 0.000 description 3
- 108010067449 Thymidylate Synthase Proteins 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 3
- 230000032823 cell division Effects 0.000 description 3
- 230000024321 chromosome segregation Effects 0.000 description 3
- 230000000295 complement Effects 0.000 description 3
- 239000000356 contaminant Substances 0.000 description 3
- 230000002354 daily Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 229960003668 docetaxel Drugs 0.000 description 3
- 230000003511 endothelial Effects 0.000 description 3
- 230000002708 enhancing Effects 0.000 description 3
- 201000010915 glioblastoma multiforme Diseases 0.000 description 3
- 150000004676 glycans Polymers 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000002489 hematologic Effects 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 230000002757 inflammatory Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 229960004768 irinotecan Drugs 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000001868 lysosomic Effects 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 201000011614 malignant glioma Diseases 0.000 description 3
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 3
- 229960001428 mercaptopurine Drugs 0.000 description 3
- 229960000485 methotrexate Drugs 0.000 description 3
- 229960000060 monoclonal antibodies Drugs 0.000 description 3
- 230000001613 neoplastic Effects 0.000 description 3
- 201000002528 pancreatic cancer Diseases 0.000 description 3
- 230000036961 partial Effects 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 150000004804 polysaccharides Polymers 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000002271 resection Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000010809 targeting technique Methods 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- CFCUWKMKBJTWLW-BGLFSJPPSA-N (2S,3S)-2-[(2S,4R,5R,6R)-4-[(2S,4R,5R,6R)-4-[(2S,4S,5R,6R)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-3-[(1S,3S,4R)-3,4-dihydroxy-1-methoxy-2-oxopentyl]-6-[(2S,4R,5S,6R)-4-[(2S,4R,5S,6R)-4,5-dih Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BGLFSJPPSA-N 0.000 description 2
- OQANPHBRHBJGNZ-FYJGNVAPSA-N (3E)-6-oxo-3-[[4-(pyridin-2-ylsulfamoyl)phenyl]hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid Chemical compound C1=CC(=O)C(C(=O)O)=C\C1=N\NC1=CC=C(S(=O)(=O)NC=2N=CC=CC=2)C=C1 OQANPHBRHBJGNZ-FYJGNVAPSA-N 0.000 description 2
- OMJKFYKNWZZKTK-UXBLZVDNSA-N (5E)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide Chemical compound CN(C)N\N=C1\N=CN=C1C(N)=O OMJKFYKNWZZKTK-UXBLZVDNSA-N 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N 1-[(1S,2R,3R,4S,5R,6R)-3-carbamimidamido-6-{[(2R,3R,4R,5S)-3-{[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy}-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy}-2,4,5-trihydroxycyclohexyl]guanidine Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 102100011141 ALK Human genes 0.000 description 2
- 108010082126 Alanine Transaminase Proteins 0.000 description 2
- 229940098174 Alkeran Drugs 0.000 description 2
- 108010005474 Anaplastic Lymphoma Kinase Proteins 0.000 description 2
- YBBLVLTVTVSKRW-UHFFFAOYSA-N Anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 2
- 206010065869 Astrocytoma, low grade Diseases 0.000 description 2
- 230000037177 Biodistribution Effects 0.000 description 2
- 229960001561 Bleomycin Drugs 0.000 description 2
- 108010006654 Bleomycin Proteins 0.000 description 2
- 210000004958 Brain cells Anatomy 0.000 description 2
- 206010006143 Brain stem glioma Diseases 0.000 description 2
- 210000000481 Breast Anatomy 0.000 description 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N Camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 2
- 210000000170 Cell Membrane Anatomy 0.000 description 2
- 210000001175 Cerebrospinal Fluid Anatomy 0.000 description 2
- HAWPXGHAZFHHAD-UHFFFAOYSA-N Chlormethine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 2
- 210000000349 Chromosomes Anatomy 0.000 description 2
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 2
- 102000020504 Collagenase family Human genes 0.000 description 2
- 108060005980 Collagenase family Proteins 0.000 description 2
- 102000003903 Cyclin-Dependent Kinases Human genes 0.000 description 2
- 108090000266 Cyclin-Dependent Kinases Proteins 0.000 description 2
- 229960004397 Cyclophosphamide Drugs 0.000 description 2
- 229960000684 Cytarabine Drugs 0.000 description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N DAUNOMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
- 108010092160 Dactinomycin Proteins 0.000 description 2
- 229960000640 Dactinomycin Drugs 0.000 description 2
- 229960000975 Daunorubicin Drugs 0.000 description 2
- ORDAZKGHSNRHTD-UXHICEINSA-N Deguelin Chemical compound O1C(C)(C)C=CC2=C1C=CC1=C2O[C@@H]2COC(C=C(C(=C3)OC)OC)=C3[C@@H]2C1=O ORDAZKGHSNRHTD-UXHICEINSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000027776 ERBB3 Human genes 0.000 description 2
- 101700041204 ERBB3 Proteins 0.000 description 2
- 230000035695 Efflux Effects 0.000 description 2
- 206010014967 Ependymoma Diseases 0.000 description 2
- 229960001433 Erlotinib Drugs 0.000 description 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N Erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 2
- 229960005420 Etoposide Drugs 0.000 description 2
- 230000036826 Excretion Effects 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- MKXKFYHWDHIYRV-UHFFFAOYSA-N Flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 2
- 102100007247 GSTP1 Human genes 0.000 description 2
- 101700055920 GSTP1 Proteins 0.000 description 2
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 2
- 229960002913 Goserelin Drugs 0.000 description 2
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 2
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 2
- 102000003964 Histone deacetylases Human genes 0.000 description 2
- 108090000353 Histone deacetylases Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 108090001095 Immunoglobulin G Proteins 0.000 description 2
- 102000003816 Interleukin-13 Human genes 0.000 description 2
- 108090000176 Interleukin-13 Proteins 0.000 description 2
- 101700048573 KLF4 Proteins 0.000 description 2
- 102100006525 KLF4 Human genes 0.000 description 2
- 210000004072 Lung Anatomy 0.000 description 2
- 101700038420 MVP Proteins 0.000 description 2
- 102100010026 MVP Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229960004961 Mechlorethamine Drugs 0.000 description 2
- 208000000172 Medulloblastoma Diseases 0.000 description 2
- 229960004857 Mitomycin Drugs 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 229920000272 Oligonucleotide Polymers 0.000 description 2
- 208000008511 Optic Nerve Glioma Diseases 0.000 description 2
- 206010073338 Optic glioma Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L Oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 2
- 108091007929 PDGF receptors Proteins 0.000 description 2
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 2
- 229960003171 Plicamycin Drugs 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 101710037934 QRSL1 Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 229920001914 Ribonucleotide Polymers 0.000 description 2
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 2
- 210000003491 Skin Anatomy 0.000 description 2
- 241001180364 Spirochaetes Species 0.000 description 2
- 229960001052 Streptozocin Drugs 0.000 description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N Streptozotocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
- 229960001940 Sulfasalazine Drugs 0.000 description 2
- 101710026335 TP53 Proteins 0.000 description 2
- 101700073473 TPT1 Proteins 0.000 description 2
- 229920003003 Telomeric non-coding RNA Polymers 0.000 description 2
- 229960003433 Thalidomide Drugs 0.000 description 2
- UEJJHQNACJXSKW-UHFFFAOYSA-N Thalidomide Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 2
- FOCVUCIESVLUNU-UHFFFAOYSA-N ThioTEPA Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 2
- 210000001685 Thyroid Gland Anatomy 0.000 description 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N Topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 2
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 229960004528 Vincristine Drugs 0.000 description 2
- 229960004355 Vindesine Drugs 0.000 description 2
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N Vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 2
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 2
- 230000001464 adherent Effects 0.000 description 2
- 229930013930 alkaloids Natural products 0.000 description 2
- 238000004164 analytical calibration Methods 0.000 description 2
- 230000002424 anti-apoptotic Effects 0.000 description 2
- 230000000692 anti-sense Effects 0.000 description 2
- 229940045698 antineoplastic Taxanes Drugs 0.000 description 2
- NOWKCMXCCJGMRR-UHFFFAOYSA-N aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000004993 binary fission Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
- 210000004781 brain capillaries Anatomy 0.000 description 2
- 229960002092 busulfan Drugs 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 230000001413 cellular Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229960002436 cladribine Drugs 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003247 decreasing Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 201000008325 diseases of cellular proliferation Diseases 0.000 description 2
- 229940000406 drug candidates Drugs 0.000 description 2
- 238000009509 drug development Methods 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 2
- 229960002074 flutamide Drugs 0.000 description 2
- 230000030279 gene silencing Effects 0.000 description 2
- 230000003054 hormonal Effects 0.000 description 2
- 229960001330 hydroxycarbamide Drugs 0.000 description 2
- VSNHCAURESNICA-UHFFFAOYSA-N hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 2
- 229940027318 hydroxyurea Drugs 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 201000000573 juvenile pilocytic astrocytoma Diseases 0.000 description 2
- 230000000670 limiting Effects 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 230000002132 lysosomal Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Polymers 0.000 description 2
- 210000000056 organs Anatomy 0.000 description 2
- 229960001756 oxaliplatin Drugs 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 230000002093 peripheral Effects 0.000 description 2
- 230000000275 pharmacokinetic Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- IJAPPYDYQCXOEF-UHFFFAOYSA-N phthalazin-1(2H)-one Chemical compound C1=CC=C2C(=O)NN=CC2=C1 IJAPPYDYQCXOEF-UHFFFAOYSA-N 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000003389 potentiating Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 229960000624 procarbazine Drugs 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- INVTYAOGFAGBOE-UHFFFAOYSA-N pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)OCC1=CC=CN=C1 INVTYAOGFAGBOE-UHFFFAOYSA-N 0.000 description 2
- 238000000163 radioactive labelling Methods 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 239000002336 ribonucleotide Substances 0.000 description 2
- 125000002652 ribonucleotide group Chemical group 0.000 description 2
- DYAHQFWOVKZOOW-UHFFFAOYSA-N sarin Chemical compound CC(C)OP(C)(F)=O DYAHQFWOVKZOOW-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- DPOPAJRDYZGTIR-UHFFFAOYSA-N tetrazine Chemical compound C1=CN=NN=N1 DPOPAJRDYZGTIR-UHFFFAOYSA-N 0.000 description 2
- 229960000303 topotecan Drugs 0.000 description 2
- 230000031998 transcytosis Effects 0.000 description 2
- 230000001131 transforming Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 238000004450 types of analysis Methods 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 description 2
- 229960002066 vinorelbine Drugs 0.000 description 2
- 230000003442 weekly Effects 0.000 description 2
- QNDVLZJODHBUFM-FCXWGWLASA-N (2R)-3-[(2S,6R,8S,11R)-2-[(E,2R)-4-[(2S,2'S,4R,4aS,6R,8aR)-4-hydroxy-2-[(1S,3S)-1-hydroxy-3-[(2S,3R,6S)-3-methyl-1,7-dioxaspiro[5.5]undecan-2-yl]butyl]-3-methylidenespiro[4a,7,8,8a-tetrahydro-4H-pyrano[3,2-b]pyran-6,5'-oxolane]-2'-yl]but-3-en-2-yl]-11-hyd Chemical compound C([C@H](O1)[C@H](C)/C=C/[C@@H]2CC[C@@]3(CC[C@H]4O[C@@H](C([C@@H](O)[C@@H]4O3)=C)[C@@H](O)C[C@H](C)[C@@H]3[C@@H](CC[C@@]4(OCCCC4)O3)C)O2)C(C)=C[C@]21O[C@H](C[C@@](C)(O)C(O)=O)CC[C@H]2O QNDVLZJODHBUFM-FCXWGWLASA-N 0.000 description 1
- PMOOKBAYUNEHOF-IKHMJLPLSA-N (2S,3S,4S,5R,6R)-6-[[(4aR,6aR,6bS,8aS,14aR,14bR)-8a-carboxy-4,4,6a,6b,11,11,14b-heptamethyl-1,2,3,4a,5,6,7,8,9,10,12,13,14,14a-tetradecahydropicen-3-yl]oxy]-3,5-dihydroxy-4-[(1R,2R,3S,4R)-2,3,4-trihydroxycyclohexyl]oxyoxane-2-carboxylic acid Chemical compound O([C@H]1[C@H](O)[C@H](O[C@H]([C@@H]1O)OC1CC[C@]2(C)[C@H]3CCC=4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@]1(CCC(CC1=4)(C)C)C(O)=O)C(O)=O)[C@@H]1CC[C@@H](O)[C@H](O)[C@H]1O PMOOKBAYUNEHOF-IKHMJLPLSA-N 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N (5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-thiophen-2-yl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- LOBCDGHHHHGHFA-LBPRGKRZSA-N (S)-monastrol Chemical compound CCOC(=O)C1=C(C)NC(=S)N[C@H]1C1=CC=CC(O)=C1 LOBCDGHHHHGHFA-LBPRGKRZSA-N 0.000 description 1
- KUFRQPKVAWMTJO-LMZWQJSESA-N 17-Dimethylaminoethylamino-17-demethoxygeldanamycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C1C2=O KUFRQPKVAWMTJO-LMZWQJSESA-N 0.000 description 1
- YAAWASYJIRZXSZ-UHFFFAOYSA-N 2,4-Diaminopyrimidine Chemical compound NC1=CC=NC(N)=N1 YAAWASYJIRZXSZ-UHFFFAOYSA-N 0.000 description 1
- CHTLVASIXCFOHC-UHFFFAOYSA-N 2,7-phenanthroline Chemical compound C1=NC=C2C3=CC=CN=C3C=CC2=C1 CHTLVASIXCFOHC-UHFFFAOYSA-N 0.000 description 1
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-Aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 1
- KMOOCZWLFBSQCW-WZVSWZHRSA-N 2-[(1R,2R,3S,4R,5R,6S)-3-(diaminomethylideneamino)-4-[(2R,3R,5S)-3-[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(2-hydroxyethyl)-3-(methylaminomethyl)oxan-2-yl]oxy-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl]guanidine;(2S,5R,6R)-3,3-dimethy Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1.CNC[C@H]1[C@H](O)[C@@H](O)[C@H](CCO)O[C@H]1O[C@@H]1C(C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O KMOOCZWLFBSQCW-WZVSWZHRSA-N 0.000 description 1
- FZDFGHZZPBUTGP-UHFFFAOYSA-N 2-[[2-[bis(carboxymethyl)amino]-3-(4-isothiocyanatophenyl)propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)C(C)CN(CC(O)=O)CC(N(CC(O)=O)CC(O)=O)CC1=CC=C(N=C=S)C=C1 FZDFGHZZPBUTGP-UHFFFAOYSA-N 0.000 description 1
- HFPLHASLIOXVGS-UHFFFAOYSA-N 2-methyl-5-(4-methylanilino)-1,3-benzothiazole-4,7-dione Chemical compound S1C(C)=NC(C2=O)=C1C(=O)C=C2NC1=CC=C(C)C=C1 HFPLHASLIOXVGS-UHFFFAOYSA-N 0.000 description 1
- IGRZXNLKVUEFDM-UHFFFAOYSA-N 2-phenyl-N-(5-propan-2-yl-1,3-thiazol-2-yl)acetamide Chemical compound S1C(C(C)C)=CN=C1NC(=O)CC1=CC=CC=C1 IGRZXNLKVUEFDM-UHFFFAOYSA-N 0.000 description 1
- VQMWCYHBHMGBDP-UHFFFAOYSA-N 2H-1,2-benzodiazepine-3,4-dione Chemical compound N1C(=O)C(=O)C=C2C=CC=CC2=N1 VQMWCYHBHMGBDP-UHFFFAOYSA-N 0.000 description 1
- WUIABRMSWOKTOF-PATWWPTKSA-N 3-[[2-[2-[2-[[(2R,3R)-2-[[(2R,3R,4S)-4-[[(2S)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2R)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2S,3R,4R,5R,6R)-3-[(2R,3S,4S,5R,6R)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)oxan- Chemical compound OS([O-])(=O)=O.N([C@H](C(=O)N[C@@H](C)[C@H](O)[C@@H](C)C(=O)N[C@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)C(O[C@@H]1[C@@H]([C@H](O)[C@@H](O)[C@@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@@H](N)C(N)=O)=NC(N)=C1C WUIABRMSWOKTOF-PATWWPTKSA-N 0.000 description 1
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 1
- QQUXFYAWXPMDOE-UHFFFAOYSA-N 9-bromo-7,12-dihydro-5H-indolo[3,2-d][1]benzazepin-6-one Chemical compound C1C(=O)NC2=CC=CC=C2C2=C1C1=CC(Br)=CC=C1N2 QQUXFYAWXPMDOE-UHFFFAOYSA-N 0.000 description 1
- 102100014002 ABCB4 Human genes 0.000 description 1
- 101700085131 ABCB4 Proteins 0.000 description 1
- 102100001249 ALB Human genes 0.000 description 1
- 229940100198 ALKYLATING AGENTS Drugs 0.000 description 1
- 229940100197 ANTIMETABOLITES Drugs 0.000 description 1
- 229960003272 ASPARAGINASE Drugs 0.000 description 1
- 102000005416 ATP-Binding Cassette Transporters Human genes 0.000 description 1
- 108010006533 ATP-Binding Cassette Transporters Proteins 0.000 description 1
- 241001114404 Acholeplasmatales Species 0.000 description 1
- 241000580482 Acidobacteria Species 0.000 description 1
- 208000004064 Acoustic Neuroma Diseases 0.000 description 1
- 241001156739 Actinobacteria <phylum> Species 0.000 description 1
- 229940009456 Adriamycin Drugs 0.000 description 1
- 206010001488 Aggression Diseases 0.000 description 1
- 229950007861 Alvespimycin Drugs 0.000 description 1
- BIIVYFLTOXDAOV-YVEFUNNKSA-N Alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 description 1
- JKOQGQFVAUAYPM-UHFFFAOYSA-N Amifostine Chemical compound NCCCNCCSP(O)(O)=O JKOQGQFVAUAYPM-UHFFFAOYSA-N 0.000 description 1
- 229960001097 Amifostine Drugs 0.000 description 1
- 229960003437 Aminoglutethimide Drugs 0.000 description 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N Aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
- 229960001220 Amsacrine Drugs 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N Amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- 241001114462 Anaeroplasmatales Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 1
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 1
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 1
- 102000018616 Apolipoproteins B Human genes 0.000 description 1
- 108010027006 Apolipoproteins B Proteins 0.000 description 1
- 102000013918 Apolipoproteins E Human genes 0.000 description 1
- 108010025628 Apolipoproteins E Proteins 0.000 description 1
- 241001142141 Aquificae <phylum> Species 0.000 description 1
- 108010078554 Aromatase Proteins 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 241000288575 Astomaea Species 0.000 description 1
- 210000001130 Astrocytes Anatomy 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 229940064856 Azulfidine Drugs 0.000 description 1
- 208000004736 B-Cell Leukemia Diseases 0.000 description 1
- 208000003950 B-Cell Lymphoma Diseases 0.000 description 1
- 210000003719 B-Lymphocytes Anatomy 0.000 description 1
- 102100019659 BAG1 Human genes 0.000 description 1
- 108091016358 BCL2-associated athanogene 1 protein Proteins 0.000 description 1
- 241000193833 Bacillales Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 240000008371 Bacillus subtilis Species 0.000 description 1
- 229940075615 Bacillus subtilis Drugs 0.000 description 1
- 241000605059 Bacteroidetes Species 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Belustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- JYZIHLWOWKMNNX-UHFFFAOYSA-N Benzimidazole Chemical compound C1=C[CH]C2=NC=NC2=C1 JYZIHLWOWKMNNX-UHFFFAOYSA-N 0.000 description 1
- 229940108502 BiCNU Drugs 0.000 description 1
- 241001430332 Bifidobacteriaceae Species 0.000 description 1
- 241001655328 Bifidobacteriales Species 0.000 description 1
- 108010071919 Bispecific Antibodies Proteins 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 210000001185 Bone Marrow Anatomy 0.000 description 1
- 210000000988 Bone and Bones Anatomy 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- JJJFUHOGVZWXNQ-UHFFFAOYSA-N Butyl cyanoacrylate Chemical compound CCCCOC(=O)C(=C)C#N JJJFUHOGVZWXNQ-UHFFFAOYSA-N 0.000 description 1
- 102100003755 CCNO Human genes 0.000 description 1
- 101700047412 CCNO Proteins 0.000 description 1
- 101710022308 CDKN1A Proteins 0.000 description 1
- 102100006400 CSF2 Human genes 0.000 description 1
- 102100005573 CYP19A1 Human genes 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- 229960004117 Capecitabine Drugs 0.000 description 1
- 102000004040 Capsid Proteins Human genes 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate dianion Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 244000132059 Carica parviflora Species 0.000 description 1
- 235000014653 Carica parviflora Nutrition 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 210000004323 Caveolae Anatomy 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 210000003855 Cell Nucleus Anatomy 0.000 description 1
- 210000002421 Cell Wall Anatomy 0.000 description 1
- 108010022830 Cetuximab Proteins 0.000 description 1
- 241001185363 Chlamydiae Species 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N Chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 241000191368 Chlorobi Species 0.000 description 1
- 241001142109 Chloroflexi Species 0.000 description 1
- 229940046978 Chlorpheniramine Maleate Drugs 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- 206010061764 Chromosomal deletion Diseases 0.000 description 1
- 241001143290 Chrysiogenetes <phylum> Species 0.000 description 1
- AMLYAMJWYAIXIA-VWNVYAMZSA-N Cilengitide Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C(C)C)N(C)C(=O)[C@H]1CC1=CC=CC=C1 AMLYAMJWYAIXIA-VWNVYAMZSA-N 0.000 description 1
- 241001112695 Clostridiales Species 0.000 description 1
- 241000192700 Cyanobacteria Species 0.000 description 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 1
- 229920001705 Cytoplasmic polyadenylation element Polymers 0.000 description 1
- 101700030105 DDX54 Proteins 0.000 description 1
- 102100001274 DDX54 Human genes 0.000 description 1
- 102100011975 DHDH Human genes 0.000 description 1
- 101700070526 DNMT1 Proteins 0.000 description 1
- 102100018208 DNMT1 Human genes 0.000 description 1
- KWHWFTSHDPJOTG-UHFFFAOYSA-N Deazaflavin Chemical compound C1=CC=C2C=C(C(=O)NC(=O)N3)C3=NC2=C1 KWHWFTSHDPJOTG-UHFFFAOYSA-N 0.000 description 1
- 206010061428 Decreased appetite Diseases 0.000 description 1
- 241001143296 Deferribacteres <phylum> Species 0.000 description 1
- 241000192095 Deinococcus-Thermus Species 0.000 description 1
- 241001135761 Deltaproteobacteria Species 0.000 description 1
- 108010043242 Denosumab Proteins 0.000 description 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N Depacane Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
- 229960004833 Dexamethasone phosphate Drugs 0.000 description 1
- 229960002344 Dexamethasone sodium phosphate Drugs 0.000 description 1
- 229960000605 Dexrazoxane Drugs 0.000 description 1
- BMKDZUISNHGIBY-ZETCQYMHSA-N Dexrazoxane Chemical compound C([C@H](C)N1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-ZETCQYMHSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000970811 Dictyoglomi Species 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 108020004461 Double-Stranded RNA Proteins 0.000 description 1
- 229940115080 Doxil Drugs 0.000 description 1
- 241000271571 Dromaius novaehollandiae Species 0.000 description 1
- 101700079760 EFCB Proteins 0.000 description 1
- 101700033006 EGF Proteins 0.000 description 1
- 102100010813 EGF Human genes 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N EPIRUBICIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- 229960001904 EPIRUBICIN Drugs 0.000 description 1
- 102100009851 ERBB4 Human genes 0.000 description 1
- 101700023619 ERBB4 Proteins 0.000 description 1
- 101710005090 ERVFC1-1 Proteins 0.000 description 1
- 101710013371 ERVS71-1 Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 210000001163 Endosomes Anatomy 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 229950005837 Entinostat Drugs 0.000 description 1
- 241001114405 Entomoplasmatales Species 0.000 description 1
- 229940116977 Epidermal Growth Factor Drugs 0.000 description 1
- 229950009760 Epratuzumab Drugs 0.000 description 1
- 241001148568 Epsilonproteobacteria Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- HKVAMNSJSFKALM-WDSGEKFTSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)\C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-WDSGEKFTSA-N 0.000 description 1
- 210000002744 Extracellular Matrix Anatomy 0.000 description 1
- 210000003414 Extremities Anatomy 0.000 description 1
- 102000027757 FGF receptors Human genes 0.000 description 1
- 108091008101 FGF receptors Proteins 0.000 description 1
- 229950009929 Farletuzumab Drugs 0.000 description 1
- PWUOOJVYZQILBG-UHFFFAOYSA-N Fascaplysine Chemical compound [Cl-].C1=CC=C2C3=CC=[N+]4C5=CC=CC=C5C(=O)C4=C3NC2=C1 PWUOOJVYZQILBG-UHFFFAOYSA-N 0.000 description 1
- 241000923108 Fibrobacteres Species 0.000 description 1
- 229950008085 Figitumumab Drugs 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N Floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 229960000961 Floxuridine Drugs 0.000 description 1
- 229960002949 Fluorouracil Drugs 0.000 description 1
- 102000016621 Focal Adhesion Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108010067715 Focal Adhesion Protein-Tyrosine Kinases Proteins 0.000 description 1
- 108009000303 Folate Metabolism Proteins 0.000 description 1
- 102000006815 Folate receptors Human genes 0.000 description 1
- 108020005243 Folate receptors Proteins 0.000 description 1
- 241001453172 Fusobacteria Species 0.000 description 1
- 102100010966 GPT Human genes 0.000 description 1
- 101700033061 GRA5 Proteins 0.000 description 1
- 229950001109 Galiximab Drugs 0.000 description 1
- 241001265526 Gemmatimonadetes <phylum> Species 0.000 description 1
- 108010091266 Gemtuzumab Proteins 0.000 description 1
- 229950002026 Girentuximab Drugs 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N Glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 229960003180 Glutathione Drugs 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 108010084340 Gonadotropin-Releasing Hormone Proteins 0.000 description 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 1
- 241000520860 Halanaerobiales Species 0.000 description 1
- 230000036499 Half live Effects 0.000 description 1
- 241001496656 Haloplasmatales Species 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 229940022353 Herceptin Drugs 0.000 description 1
- 241000405147 Hermes Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 108010064750 Humanized Monoclonal Antibodies Proteins 0.000 description 1
- 102000015434 Humanized Monoclonal Antibodies Human genes 0.000 description 1
- 240000006600 Humulus lupulus Species 0.000 description 1
- 235000008694 Humulus lupulus Nutrition 0.000 description 1
- 108010024848 IMC-3G3 Proteins 0.000 description 1
- 229960000908 Idarubicin Drugs 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin hydrochloride Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- 241000370541 Idia Species 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N Ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229960001101 Ifosfamide Drugs 0.000 description 1
- 102000018358 Immunoglobulins Human genes 0.000 description 1
- 108060003951 Immunoglobulins Proteins 0.000 description 1
- 229950002133 Iniparib Drugs 0.000 description 1
- MDOJTZQKHMAPBK-UHFFFAOYSA-N Iniparib Chemical compound NC(=O)C1=CC=C(I)C([N+]([O-])=O)=C1 MDOJTZQKHMAPBK-UHFFFAOYSA-N 0.000 description 1
- 108050003490 Insulin-like growth factor Proteins 0.000 description 1
- 102000014429 Insulin-like growth factor Human genes 0.000 description 1
- 108010072255 Integrin alpha3beta1 Proteins 0.000 description 1
- 241000895880 Ioa Species 0.000 description 1
- 108010089187 Ipilimumab Proteins 0.000 description 1
- 101710033922 KRAS Proteins 0.000 description 1
- 206010023424 Kidney infection Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 102000000853 LDL receptors Human genes 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- 241001112724 Lactobacillales Species 0.000 description 1
- 241001387859 Lentisphaerae Species 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 241001609976 Leuconostocaceae Species 0.000 description 1
- 229940063725 Leukeran Drugs 0.000 description 1
- 229940008250 Leuprolide Drugs 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 229960004338 Leuprorelin Drugs 0.000 description 1
- 102000011965 Lipoprotein Receptors Human genes 0.000 description 1
- 108010061306 Lipoprotein Receptors Proteins 0.000 description 1
- 241001112727 Listeriaceae Species 0.000 description 1
- 229940100029 Lysodren Drugs 0.000 description 1
- 108050005300 MDM4 Proteins 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 210000002540 Macrophages Anatomy 0.000 description 1
- WKPWGQKGSOKKOO-RSFHAFMBSA-N Maitansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 1
- 206010025650 Malignant melanoma Diseases 0.000 description 1
- 241001446467 Mama Species 0.000 description 1
- 229940087732 Matulane Drugs 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 208000007650 Meningeal Carcinomatosis Diseases 0.000 description 1
- 206010027191 Meningioma Diseases 0.000 description 1
- 206010051696 Metastases to meninges Diseases 0.000 description 1
- 206010027476 Metastasis Diseases 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N Mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 229960001156 Mitoxantrone Drugs 0.000 description 1
- 229950007812 Mocetinostat Drugs 0.000 description 1
- 241001430197 Mollicutes Species 0.000 description 1
- 210000001616 Monocytes Anatomy 0.000 description 1
- 210000000865 Mononuclear Phagocyte System Anatomy 0.000 description 1
- 108090000393 Muromonab-CD3 Proteins 0.000 description 1
- 229960003816 Muromonab-CD3 Drugs 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 241000204003 Mycoplasmatales Species 0.000 description 1
- 229940090009 Myleran Drugs 0.000 description 1
- HRNLUBSXIHFDHP-UHFFFAOYSA-N N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC1=NC=CC(C=2C=NC=CC=2)=N1 HRNLUBSXIHFDHP-UHFFFAOYSA-N 0.000 description 1
- KCTZOTUQSGYWLV-UHFFFAOYSA-N N1C=NC=C2N=CC=C21 Chemical compound N1C=NC=C2N=CC=C21 KCTZOTUQSGYWLV-UHFFFAOYSA-N 0.000 description 1
- 101700045188 NSG1 Proteins 0.000 description 1
- 241001182492 Nes Species 0.000 description 1
- 208000007538 Neurilemmoma Diseases 0.000 description 1
- 229950010203 Nimotuzumab Drugs 0.000 description 1
- 241000121237 Nitrospirae Species 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 241001655308 Nocardiaceae Species 0.000 description 1
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 description 1
- 108009000071 Non-small cell lung cancer Proteins 0.000 description 1
- 229920001850 Nucleic acid sequence Polymers 0.000 description 1
- 229950007318 OZOGAMICIN Drugs 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229960002450 Ofatumumab Drugs 0.000 description 1
- LZMPYSIUWPEIRA-XFXZXTDPSA-N Ofatumumab Chemical compound N1=C2C=3COCCC=3N=CC2=N\C1=C1\NOC=C1 LZMPYSIUWPEIRA-XFXZXTDPSA-N 0.000 description 1
- FAQDUNYVKQKNLD-UHFFFAOYSA-N Olaparib Chemical compound FC1=CC=C(CC2=C3[CH]C=CC=C3C(=O)N=N2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FAQDUNYVKQKNLD-UHFFFAOYSA-N 0.000 description 1
- GTVPOLSIJWJJNY-UHFFFAOYSA-N Olomoucine Chemical compound N1=C(NCCO)N=C2N(C)C=NC2=C1NCC1=CC=CC=C1 GTVPOLSIJWJJNY-UHFFFAOYSA-N 0.000 description 1
- 229950002610 Otelixizumab Drugs 0.000 description 1
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 1
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 1
- 102100015381 PTGS2 Human genes 0.000 description 1
- 229950010626 Pagibaximab Drugs 0.000 description 1
- WRUUGTRCQOWXEG-UHFFFAOYSA-N Pamidronic acid Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 1
- 108010061219 Panitumumab Proteins 0.000 description 1
- FWZRWHZDXBDTFK-ZHACJKMWSA-N Panobinostat Chemical compound CC1=NC2=CC=C[CH]C2=C1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FWZRWHZDXBDTFK-ZHACJKMWSA-N 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 241001135902 Peanut clump virus Species 0.000 description 1
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N Pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 1
- 229940049954 Penicillin Drugs 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229960002340 Pentostatin Drugs 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N Pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 210000000680 Phagosomes Anatomy 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N Phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 229960002695 Phenobarbital Drugs 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 206010061538 Pituitary tumour benign Diseases 0.000 description 1
- 210000002381 Plasma Anatomy 0.000 description 1
- 229940063179 Platinol Drugs 0.000 description 1
- 102000012425 Polycomb-Group Proteins Human genes 0.000 description 1
- 108010022429 Polycomb-Group Proteins Proteins 0.000 description 1
- 229940068968 Polysorbate 80 Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N Prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- QTTMOCOWZLSYSV-QWAPEVOJSA-M Premarin Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 QTTMOCOWZLSYSV-QWAPEVOJSA-M 0.000 description 1
- 210000002307 Prostate Anatomy 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 241000192142 Proteobacteria Species 0.000 description 1
- 102000015690 Proto-Oncogene Proteins c-bcr Human genes 0.000 description 1
- 108010024221 Proto-Oncogene Proteins c-bcr Proteins 0.000 description 1
- 102000001309 Proto-Oncogene Proteins c-mdm2 Human genes 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- 229940117820 Purinethol Drugs 0.000 description 1
- 101700007719 RAF1 Proteins 0.000 description 1
- 101700020165 RHOA Proteins 0.000 description 1
- 102000004409 RNA helicases Human genes 0.000 description 1
- 108090000944 RNA helicases Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000007312 Recombinant Proteins Human genes 0.000 description 1
- 108010033725 Recombinant Proteins Proteins 0.000 description 1
- 208000008938 Rhabdoid Tumor Diseases 0.000 description 1
- 206010073334 Rhabdoid tumour Diseases 0.000 description 1
- 108010001645 Rituximab Proteins 0.000 description 1
- HNMATTJJEPZZMM-BPKVFSPJSA-N S-[(2R,3S,4S,6S)-6-[[(2R,3S,4S,5R,6R)-5-[(2S,4S,5S)-5-[acetyl(ethyl)amino]-4-methoxyoxan-2-yl]oxy-6-[[(2S,5Z,9R,13E)-13-[2-[[4-[(2E)-2-[1-[4-(4-amino-4-oxobutoxy)phenyl]ethylidene]hydrazinyl]-2-methyl-4-oxobutan-2-yl]disulfanyl]ethylidene]-9-hydroxy-12-(m Chemical compound C1[C@H](OC)[C@@H](N(CC)C(C)=O)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@@](C/3=C/CSSC(C)(C)CC(=O)N\N=C(/C)C=3C=CC(OCCCC(N)=O)=CC=3)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HNMATTJJEPZZMM-BPKVFSPJSA-N 0.000 description 1
- 101700025193 SRK2D Proteins 0.000 description 1
- 206010039667 Schwannoma Diseases 0.000 description 1
- BTIHMVBBUGXLCJ-OAHLLOKOSA-N Seliciclib Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@@H](CO)CC)=NC=1NCC1=CC=CC=C1 BTIHMVBBUGXLCJ-OAHLLOKOSA-N 0.000 description 1
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 1
- 229950007874 Solanezumab Drugs 0.000 description 1
- 241000230565 Sphingobacteriia Species 0.000 description 1
- 241000194018 Streptococcaceae Species 0.000 description 1
- 229960005322 Streptomycin Drugs 0.000 description 1
- 208000001662 Subependymal Glioma Diseases 0.000 description 1
- 206010042602 Supraventricular extrasystoles Diseases 0.000 description 1
- 102400000368 Surface protein Human genes 0.000 description 1
- 241000282890 Sus Species 0.000 description 1
- 210000001744 T-Lymphocytes Anatomy 0.000 description 1
- 101710029715 TCEAL1 Proteins 0.000 description 1
- 101700083028 TNKS Proteins 0.000 description 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- 102100019730 TP53 Human genes 0.000 description 1
- 108060008443 TPPP Proteins 0.000 description 1
- 102100018690 TPT1 Human genes 0.000 description 1
- 241000375392 Tana Species 0.000 description 1
- AYUNIORJHRXIBJ-TXHRRWQRSA-N Tanespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCC=C)C(=O)C=C1C2=O AYUNIORJHRXIBJ-TXHRRWQRSA-N 0.000 description 1
- 229950007866 Tanespimycin Drugs 0.000 description 1
- 229950008160 Tanezumab Drugs 0.000 description 1
- 229940120982 Tarceva Drugs 0.000 description 1
- 229940063683 Taxotere Drugs 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temodal Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- 229940061353 Temodar Drugs 0.000 description 1
- 241000131694 Tenericutes Species 0.000 description 1
- 229960001278 Teniposide Drugs 0.000 description 1
- 229950010127 Teplizumab Drugs 0.000 description 1
- 229940034915 Thalomid Drugs 0.000 description 1
- 241000970807 Thermoanaerobacterales Species 0.000 description 1
- 241001143310 Thermotogae <phylum> Species 0.000 description 1
- 229960001196 Thiotepa Drugs 0.000 description 1
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 1
- 229950007217 Tremelimumab Drugs 0.000 description 1
- YCPOZVAOBBQLRI-WDSKDSINSA-N Treosulfan Chemical compound CS(=O)(=O)OC[C@H](O)[C@@H](O)COS(C)(=O)=O YCPOZVAOBBQLRI-WDSKDSINSA-N 0.000 description 1
- 229960001099 Trimetrexate Drugs 0.000 description 1
- NOYPYLRCIDNJJB-UHFFFAOYSA-N Trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 230000036462 Unbound Effects 0.000 description 1
- 108020004417 Untranslated RNA Proteins 0.000 description 1
- 108091007928 VEGF receptors Proteins 0.000 description 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
- 210000003462 Veins Anatomy 0.000 description 1
- 241001261005 Verrucomicrobia Species 0.000 description 1
- 241000863480 Vinca Species 0.000 description 1
- BPQMGSKTAYIVFO-UHFFFAOYSA-N Vismodegib Chemical compound ClC1=CC(S(=O)(=O)C)=CC=C1C(=O)NC1=CC=C(Cl)C(C=2N=CC=CC=2)=C1 BPQMGSKTAYIVFO-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 229960000237 Vorinostat Drugs 0.000 description 1
- WAEXFXRVDQXREF-UHFFFAOYSA-N Vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 1
- 241000282485 Vulpes vulpes Species 0.000 description 1
- 201000005806 Western equine encephalitis Diseases 0.000 description 1
- 229950008250 Zalutumumab Drugs 0.000 description 1
- 229950009002 Zanolimumab Drugs 0.000 description 1
- 229940033942 Zoladex Drugs 0.000 description 1
- QTQAWLPCGQOSGP-DVKIRIBLSA-N [(3R,5R,6S,7R,8E,10R,11R,12E,14E)-6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate Chemical compound N1C(=O)\C(C)=C\C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C\[C@@H](C)[C@H](O)[C@H](OC)C[C@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-DVKIRIBLSA-N 0.000 description 1
- 238000009557 abdominal ultrasonography Methods 0.000 description 1
- 230000001594 aberrant Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000002378 acidificating Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229940050528 albumin Drugs 0.000 description 1
- 230000002152 alkylating Effects 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 201000003076 angiosarcoma Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000006909 anti-apoptosis Effects 0.000 description 1
- 230000000118 anti-eoplastic Effects 0.000 description 1
- 230000003110 anti-inflammatory Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940045985 antineoplastic drugs Platinum compounds Drugs 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 101700004528 arp Proteins 0.000 description 1
- 230000017047 asymmetric cell division Effects 0.000 description 1
- 125000004429 atoms Chemical group 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 1
- 229960000626 benzylpenicillin Drugs 0.000 description 1
- 230000005250 beta ray Effects 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- 230000002146 bilateral Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000003115 biocidal Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 108010034406 briakinumab Proteins 0.000 description 1
- 229960002874 briakinumab Drugs 0.000 description 1
- 108010036787 canakinumab Proteins 0.000 description 1
- 229960001838 canakinumab Drugs 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 201000009030 carcinoma Diseases 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000027448 caveolin-mediated endocytosis Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000003850 cellular structures Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 230000000973 chemotherapeutic Effects 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 229960003291 chlorphenamine Drugs 0.000 description 1
- 230000002759 chromosomal Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- 238000010192 crystallographic characterization Methods 0.000 description 1
- 230000001086 cytosolic Effects 0.000 description 1
- 230000001472 cytotoxic Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 108010020644 dalotuzumab Proteins 0.000 description 1
- 229960002482 dalotuzumab Drugs 0.000 description 1
- 230000004059 degradation Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 229960001251 denosumab Drugs 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- PLCQGRYPOISRTQ-FCJDYXGNSA-L dexamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-FCJDYXGNSA-L 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 201000008286 diarrhea Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000009910 diseases by infectious agent Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229950010048 enbucrilate Drugs 0.000 description 1
- 230000004651 endocytosis pathway Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002255 enzymatic Effects 0.000 description 1
- 210000002919 epithelial cells Anatomy 0.000 description 1
- 108010007604 epratuzumab Proteins 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229960005167 everolimus Drugs 0.000 description 1
- 230000003203 everyday Effects 0.000 description 1
- 108010087285 farletuzumab Proteins 0.000 description 1
- 230000002349 favourable Effects 0.000 description 1
- 101710004779 fba1 Proteins 0.000 description 1
- 230000001605 fetal Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 108010025050 figitumumab Proteins 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- 229960005304 fludarabine phosphate Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000003260 fluorescence intensity Methods 0.000 description 1
- 150000002224 folic acids Chemical class 0.000 description 1
- 108010012206 galiximab Proteins 0.000 description 1
- 230000005251 gamma ray Effects 0.000 description 1
- 230000002496 gastric Effects 0.000 description 1
- 229960000578 gemtuzumab Drugs 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 230000002518 glial Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000001963 growth media Substances 0.000 description 1
- 230000002962 histologic Effects 0.000 description 1
- 230000002706 hydrostatic Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001771 impaired Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000000977 initiatory Effects 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 230000000968 intestinal Effects 0.000 description 1
- 229940079866 intestinal antibiotics Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- 230000002427 irreversible Effects 0.000 description 1
- PXZQEOJJUGGUIB-UHFFFAOYSA-N isoindolin-1-one Chemical compound C1=CC=C2C(=O)NCC2=C1 PXZQEOJJUGGUIB-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- VDBNYAPERZTOOF-UHFFFAOYSA-N isoquinolin-1(2H)-one Chemical compound C1=CC=C2C(=O)NC=CC2=C1 VDBNYAPERZTOOF-UHFFFAOYSA-N 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 230000003902 lesions Effects 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- GZQKNULLWNGMCW-PWQABINMSA-J lipid A(4-) Chemical compound O1[C@H](CO)[C@@H](OP([O-])([O-])=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP([O-])([O-])=O)O1 GZQKNULLWNGMCW-PWQABINMSA-J 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000034701 macropinocytosis Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000003340 mental Effects 0.000 description 1
- 108010062313 mepolizumab Proteins 0.000 description 1
- 229960005108 mepolizumab Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 108060004913 minE Proteins 0.000 description 1
- ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 1
- 201000004058 mixed glioma Diseases 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- 108060007643 mukB Proteins 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 101700045377 mvp1 Proteins 0.000 description 1
- 239000005445 natural product Substances 0.000 description 1
- 229930014626 natural products Natural products 0.000 description 1
- 108010033813 necitumumab Proteins 0.000 description 1
- 229960000513 necitumumab Drugs 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 108010043585 nimotuzumab Proteins 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229920001894 non-coding RNA Polymers 0.000 description 1
- 230000000683 nonmetastatic Effects 0.000 description 1
- 108010052070 ofatumumab Proteins 0.000 description 1
- 229960000572 olaparib Drugs 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic Effects 0.000 description 1
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 1
- 230000003287 optical Effects 0.000 description 1
- 101700009395 orf8 Proteins 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 108010009925 otelixizumab Proteins 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 150000005623 oxindoles Chemical class 0.000 description 1
- 108010054892 pagibaximab Proteins 0.000 description 1
- 229940046231 pamidronate Drugs 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 229960005184 panobinostat Drugs 0.000 description 1
- 230000001575 pathological Effects 0.000 description 1
- 229960005079 pemetrexed Drugs 0.000 description 1
- 210000003668 pericytes Anatomy 0.000 description 1
- 230000005043 peripheral vision Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 108010042024 pertuzumab Proteins 0.000 description 1
- 229960002087 pertuzumab Drugs 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000003285 pharmacodynamic Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000003114 pinocytic Effects 0.000 description 1
- 201000005746 pituitary adenoma Diseases 0.000 description 1
- 150000003058 platinum compounds Chemical class 0.000 description 1
- 101700016463 pls Proteins 0.000 description 1
- 229930001140 podophyllotoxin Natural products 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 230000001124 posttranscriptional Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002335 preservative Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001737 promoting Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- PMXCMJLOPOFPBT-HNNXBMFYSA-N purvalanol A Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@@H](CO)C(C)C)=NC=1NC1=CC=CC(Cl)=C1 PMXCMJLOPOFPBT-HNNXBMFYSA-N 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- GZTPJDLYPMPRDF-UHFFFAOYSA-N pyrrolo[3,2-c]pyrazole Chemical compound N1=NC2=CC=NC2=C1 GZTPJDLYPMPRDF-UHFFFAOYSA-N 0.000 description 1
- 230000005258 radioactive decay Effects 0.000 description 1
- 239000003247 radioactive fallout Substances 0.000 description 1
- 108010026911 ramucirumab Proteins 0.000 description 1
- 229960002633 ramucirumab Drugs 0.000 description 1
- 230000000306 recurrent Effects 0.000 description 1
- 230000002829 reduced Effects 0.000 description 1
- 108010069061 reslizumab Proteins 0.000 description 1
- 229960003254 reslizumab Drugs 0.000 description 1
- 230000000717 retained Effects 0.000 description 1
- 150000004508 retinoic acid derivatives Chemical class 0.000 description 1
- 230000002441 reversible Effects 0.000 description 1
- 201000006402 rhabdoid cancer Diseases 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 229960003452 romidepsin Drugs 0.000 description 1
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 1
- 108010091666 romidepsin Proteins 0.000 description 1
- 229960002530 sargramostim Drugs 0.000 description 1
- 108010038379 sargramostim Proteins 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 230000001743 silencing Effects 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 108010079667 solanezumab Proteins 0.000 description 1
- 239000002047 solid lipid nanoparticle Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000028070 sporulation Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000000153 supplemental Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 238000009121 systemic therapy Methods 0.000 description 1
- 108010038329 tanezumab Proteins 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 108010018121 teplizumab Proteins 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 230000001971 thyroidal Effects 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N tin hydride Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 102000002689 toll-like receptors Human genes 0.000 description 1
- 108020000411 toll-like receptors Proteins 0.000 description 1
- 229960005267 tositumomab Drugs 0.000 description 1
- 231100000224 toxic side effect Toxicity 0.000 description 1
- 108010039246 trans-1,2-dihydrobenzene-1,2-diol dehydrogenase Proteins 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 108010072993 tremelimumab Proteins 0.000 description 1
- 229960003181 treosulfan Drugs 0.000 description 1
- 239000000225 tumor suppressor protein Substances 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
- 108010035693 vedolizumab Proteins 0.000 description 1
- 229960004914 vedolizumab Drugs 0.000 description 1
- KDQAABAKXDWYSZ-JKDPCDLQSA-N vincaleukoblastine sulfate Chemical compound OS(O)(=O)=O.C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 KDQAABAKXDWYSZ-JKDPCDLQSA-N 0.000 description 1
- 230000003612 virological Effects 0.000 description 1
- 229960004449 vismodegib Drugs 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 101700012276 wos2 Proteins 0.000 description 1
- 108010023055 zalutumumab Proteins 0.000 description 1
- 108010052251 zanolimumab Proteins 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
- A61K51/109—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin immunoglobulins having two or more different antigen-binding sites or multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1203—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules in a form not provided for by groups A61K51/1206 - A61K51/1296, e.g. cells, cell fragments, viruses, virus capsides, ghosts, red blood cells, viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
- A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Abstract
Disclosed is the use of a composition in the manufacture of a medicament for treating a brain tumour, wherein the composition comprises a plurality of intact, bacterially derived minicells, and wherein: (A) each minicell of the plurality (i) comprises an antibody that specifically recognizes a tumour cell antigen and (ii) encompasses an anti-neoplastic agent; and (B) the brain tumour has blood vessels with fenestrations in its walls through which the minicells can extravasate passively. ur cell antigen and (ii) encompasses an anti-neoplastic agent; and (B) the brain tumour has blood vessels with fenestrations in its walls through which the minicells can extravasate passively.
Description
PCT/1B2012/002950
BACTERIALLY DERIVED, INTACT MINICELLS FOR
DELIVERY OF THERAPEUTIC AGENTS TO BRAIN TUMORS
CROSS-REFERENCE TO RELATED APPLICATIONS
This application claims benefit of priority to US. provisional application serial
No.6l/569,907, filed December 13, 2011, the contents of which are incorporated by
reference here in their entirety.
BACKGROUND
Primary brain tumors consist of a diverse group of sms, derived from various
different cell es. Pursuant to a World Health Organization categorization (Louis 22‘ a/.,
2007), tumors of the central nervous system are classified as astroeytic, oligodendroglial, or
mixed (oligoastrocytie). These tumors are further classified by subtypes and are graded,
based on histology, from I to IV, with grade IV being the most sive. Glioblastoma
multiforme (GBM), the most aggressive form of primary malignant brain tumor, accounts for
approximately 45% to 50% of all primary brain tumors (Wrensch er al., 2002; Behin er a/.,
2003) and represents the second largest cause of cancer death in adults under 35 years of age
(Allard er al., 2009).
Despite numerous eutic efforts, including cytoreduetive surgery, radiation
therapy and chemotherapy, the prognosis for glioma patients remains very poor (Stewart,
2002; Stupp et a/., 2005). A majority eventually develop recurrent and progressive disease,
after which the median al is approximately 6 months (Wong et a/., 1999; Lambom et
a/., 2008). Median survival for GBM patients is about 12~14 months (Stupp et a/., 2005).
{0004] In on, brain metastasis from primary tumors such as breast, lung, and skin
(melanoma) is a significant and g public health problem. An estimated 250,000
patients in the United States were diagnosed with brain metastases in 2009 (Fox et (11., 201 l),
which is more than 10-fold r than the nce of primary brain tumors (Jemal er al.,
2009). The prognosis for ts with brain metastases is very poor, and most ts live
only 4—6 months after diagnosis. Current treatment regimens provide marginal survival
benefits (Eichler and Loeffler, 2007).
W0 2013/088250 PCT/[32012/002950
Complete al resection of gliomas is almost impossible, due to their diffusely
infiltrative nature and proximity to vital brain structures. Systemic therapy also is limited, by
virtue of the so-called blood brain barrier (BBB). See, generally, Cecchelli et al. (2007).
This barrier resides within the brain's capillary endothclium, and it has been an object
of study for over 100 years. Indeed, the fact that most drug candidates for brain tumors never
make it to the clinic idge, 2007) is attributable largely to their inability to cross the
BBB and reach levels having a therapeutic effect (Groothuis, 2000).
Despite extensive efforts over l decades, the curative rates in the treatment of
brain cancers remain abysmal. Brain cancer treatment thus represents one of the biggest
challenges in oncology. Furthermore, the prevailing consensus is that the BBB is the major
limiting factor in drug delivery into brain .
Accordingly, considerable effort is directed ly to discovering and developing
new drugs that are small enough to cross the BBB and improve the survival outcome for
GBM patients. In addition, ques are under development to transport drugs past the
BBB and into the brain tumor microenvironmcnt.
Among the approaches that have been d, in an attempt to circumvent the BBB
limitation, are the following.
° Hyperosmotic BBB disruption (Kroll and Neuwelt, I998).
° Chemical r modification (Black et (11., 1997).
° Attempts to link therapeutic agents to compounds that have transporters across the BBB
(Biekel et a]. , 2001; Zhang and Pardridge, 2007).
' Direct administration of drugs into and around brain tumors (Hassenbuseh et al., 2002;
Han er 0]., 2002; Reardon et al., 2002; Weber et al., 2002). This approach entails
placement of drug-loaded wafers around a tumor resection bed, infusion of agents into
or around a tumor resection cavity, or direct infusion of drugs into the tumor mass.
Convection-Enhanced Delivery or “CED” (Bobo er 0]., 1994; on et al., 1994;
Hadjipanayis er al., 2008; Hadjipanayis et (11., 2010). In CED a small hydrostatic
pressure differential is imposed by a syringe pump to bute te directly to
s of the central nervous system (CNS). CED is a minimally invasive surgical
procedure that provides fluid convection in the brain by a pressure gradient, which
bypasses the BBB. Therapeutic agents can be delivered into the brain with a minimum
of the toxicity, therefore, as well as to normal tissue and to organs commonly accessed
by systemic delivery.
SUMMARY
In view of the drawbacks affecting conventional approaches in this area, a method is
disclosed for administering systemically a therapeutically effective amount of a composition
comprised of a plurality of intact, bacterially derived minicells, where each minicell of the
plurality encompasses an anti-neoplastic agent. By the same token, the present ption
contemplates the use of such composition for cture of a medicament for the treatment
of a brain tumor. The plurality can include at least about 108 minicells, including but not
limited to at least about 1010 minicells. Also, a composition as described here can contain
less than about 10 EU free endotoxin and/or at most 1 parent bacterial cell per 108 lls,
e.g., per 10'0 minicells.
A first aspect of the invention provides use of a composition in the manufacture
of a medicament for treating a brain tumor, n the composition comprises a plurality of
, bacterially d minicells, and n:
(A) each minicell of said plurality (i) ses an antibody that specifically
recognizes a tumor cell antigen and (ii) encompasses an anti—neoplastic agent; and
(B) the brain tumor has blood vessels with fenestrations in its walls h which
the lls can extravasate passively.
[0010b] A second aspect of the invention provides use of a plurality of intact, bacterially
derived minicells in the cture of a medicament for treating a brain tumor, wherein:
(A) each minicell of said plurality (i) comprises an antibody that specifically
recognizes a tumor cell antigen and (ii) encompasses an anti—neoplastic agent; and
(B) the brain tumor has blood vessels with fenestrations in its walls through which
the minicells can extravasate passively.
The anti-neoplastic agent encompassed by the minicells can be a radionuclide, for
example, such as m-90, technetium-99m, iodine-123, iodine-131, rubidium-82,
thallium-201, gallium-67, fluorine-l 8, xenon-133, or indium-1 l 1, which can be attached to a
protein or a carbohydrate on the e ofthe minicells, or it can be attached on the surface
8634093_1 (GHMalIars) P97227tNZ LEOWNR 2-Jul-IS
of the tumor targeting ligand attached on the surface of the minicells. In this context, the
ition can contain, for instance, between about 30 Gy to about 100 Gy ctivity.
The anti-neoplastic agent also can be a chemotherapy drug, where, for example, the
composition contains at most about 1 mg thereof. Moreover, the anti-neoplastic agent can be
a functional nucleic acid or a polynucleotide ng a functional nucleic acid. Thus, the
functional nucleic acid can inhibit a gene that promotes tumor cell proliferation, angiogenesis
or resistance to chemotherapy and/or that inhibits apoptosis or cell cycle arrest. Illustrative
0fthe class of functional nucleic acids are ribonucleic acid molecules selected from the group
consisting of siRNA, miRNA, shRNA, lincRNA, antisense RNA, and ribozyme.
Pursuant to certain embodiments in ance with any of the foregoing, each
minicell ofthe above-mentioned ity can comprise a ligand having a specificity to a non-
phagocytic mammalian cell e receptor, e.g., a tumor cell antigen. Accordingly, the
ligand can comprise, for instance, an antibody that cally recognizes such tumor cell
antigen.
The methodology of this description can be used to treat a range of brain ,
illustrated by but not limited to the group consisting of glioblastoma, astrocytic tumor,
oligodendroglial tumor, moma, craniopharyngioma, pituitary tumor, primary
lymphoma of the brain, pineal gland tumor, primary germ cell tumor of the brain, and
combinations thereof. The treated tumor can be a primary brain tumor or a metastatic brain
tumor.
Other features and advantages are apparent from the following detailed description.
The detailed description and specific es are given for illustration only, since various
changes and modifications within the Spirit and scope of the particular embodiments will
become apparent from this description.
BRIEF DESCRIPTION OF THE DRAWINGS
FIGURE 1. EGF receptor quantitation on human (U87-MG) and canine brain tumor
cells, which were treated with anti-EGFR MAb, followed by R-phycoerythrin conjugated
goat anti-mouse IgG. The cells were analyzed using FACS and were compared with
fluorescent R-phycoerythrin microbead standards. Control cells were treated in the same
manner, except for the y antibody. EGFR tation results revealed an EGFR
663t093_1 (GHMaiiars) P97227.NZ LEOVVNR 2~Jul-15
concentration per cell (in a decreasing order) for BCD-l, U87-MG, BCD—9, BCD-8 and J3T
cells was 2,866,854, 1,465,755, 930,440, 774,352 and 287,622, respectively. s for
each cell line are shown as control s with dark border) and anti-EGFR MAb-treated
(curves without dark border).
FIGURE 2. Results are shown of a cell proliferation (MTS) assay to determine
doxorubicin sensitivity of canine and human (U87-MG) brain cancer cells. Error bars, :t
SEM.
FIGURE 3. Representative histograms from FACS analyses show the efficiency of
binding of EGFRminicellsDox to canine and human brain cancer cells. > 95% of the cells in
each case showed cant binding of EGFRminicellsDox. Cells treated with non-specifically
6634093_| (GHMBIIers) P9722? NZ LEOWNR 2-Jul-15
WO 88250 PCT/[32012/002950
targeted sq3'mininiccllspox did not display any binding to the cells. Anti-gplZO antibody is
directed to HIV viral capsid protein gp120, which is not found on any of the tumor cells.
FIGURE 4. Human and canine brain tumor cells were treated with Izcmminieellsmx
and control 3" 120minicellsD0x for 3 hours. Minicells bound to the tumor cells were visualized
following treatment with goat anti-mouse AF488 (green fluorescence, shown r
stippling), which binds to the PS component (IgG2a) of a bispecific antibody used to
target the respective minicells. The right-hand image or each vertical panel is visualized for
dox autofluorescence (red fluorescence, as darker stippling) and shows that the dox is within
the s of most ected cells. The images were captured using Leica fluorescence
microscope. Scale bar, 20 um.
FIGURE 5. Tumor stabilization/regression in seven dogs with late-stage brain
EGFRminicellsDox.
tumors, post-treatment with MRI scans prior to treatment (Pre Dose) for
each dog are shown in the left-hand vertical . The middle- and the right~hand vertical
columns Show MRI scans, reatment with FGFRminicellsmx, and the post-dose number is
shown for each MR1. The depicted MRI sections include sagittal (BCD-l and -6), axial
(BCD-2 to -5) and coronal (BCD-7). Tumor volumes (dimensions in cm) are shown below
each MRI, and an arrow denotes the location of the respective tumors.
FIGURE 6. Serum mistry parameters were determined, post-treatment, for
seven dogs with brain cancers (BCD-l to BCD7). The horizontal lines in each graph
represent the normal reference range in canines. Error bars, :t SEM.
FIGURE 7. Serum hematology parameters determined post-treatment of seven dogs
with brain cancers (BCD-l to BCD7). The horizontal lines in each graph represent the
normal reference range in canines. Error bars, i SEM.
FIGURE 8. Serum TNFa, IL—6, and lL-lO responses are illustrated in the seven brain
cancer dogs, post treatment with EGFRminicellsDox.
FIGURE 9. Depicted are anti-LPS dy responses in 7 brain cancer dogs
(survival), post-treatment with EGFRminicellsnm‘.
FIGURE 10. Survival (in days) is illustrated for the 7 dogs with brain cancer (left
hand y-axis and represented with bars), along with number of doses of EGFRminicellsD0x
PCT/132012/002950
administered (right hand y-axis and shown as diamonds associated with each bar). Striped
bars indicate dogs that are on-going and in remission. Darker solid bars indicate dogs that
showed stable disease until the tumor recurred, possibly due to development of dox-
resistance, and these dogs were euthanized. The lighter solid bar is for a dog that was in
remission but died due to an unrelated infection.
FIGURE 11. (a) The co-registered T1 post~contrast MRI and SPECT scans are shown
separately, (i) and (iii), and in a fused image display (ii) in the three orthogonal planes
al, sagittal, and transaxial). The area of uptake and the region to which it was zed
are indicated by the arrows. The uptake was lower than in the extra-cerebral foci, seen
bilaterally on either side of the head, but it was the only uptake observed inside the brain.
(b) Results are shown for r animal. The transaxial views only are displayed for
MRI (i) and SPECT (iii). e uptake is evident in the abnormality demonstrated on MRI.
Image (ii) is a istcred display of T] post~contrast MRI, SPECT, and fused images. The
arrows te an area of intense localization of radiolabelled minicells, which corresponded
to a portion ofthe abnormality on the MRI scan.
(c) Shown are whole-body, 2D planar images at 30 minutes and 3 hours post-injection.
Along with thyroid and some neck uptake, early uptake is seen in liver, with some excretion
into bowel visible in the late scans.
FIGURE 12. Human atic cancer (MIA PaCa) xenografts in Balb/c nu/nu mice
(n — 8 per group) were administered iv with either free Gemcitabine (Gemzar®) or EGFR-
targeted, Gemzar-packaged minicells (EGFRMIDICGHSGcmznr). All minicell treatments received
109 minicells per dose. Treatment days are shown below the x-axis (triangles). Error bars:
+/- SEM. The chart shows tumor volume at indicated days following the administration.
. 13. Human breast cancer (MDA-MB-468) xenografts in Balb/c nu/nu
mice (n = 8 per group) were administered iv. with free carboplatin or with minicells,
packaged with carboplatin, that are either non-targeted or EGFR-targeted
(EGFRMinicellsCMbopmin). All minicell treatments ed 109 minicells per dose. Treatment
days are shown below the x-axis (arrows). Error bars: +/- SEM. The chart shows tumor
volume at indicated days following the administration.
W0 2013/088250 PCT/[82012/002950
DETAILED DESCRIPTION
The present disclosure provides compositions and methods for the treatment of brain
tumors. In this respect, the inventors discovered that intact, bacterially derived minicells
packaged with one or more anti-neoplastic agents, upon systemic administration, rapidly
accumulate in the mieroenvironmcnt of a brain tumor, in therapeutically significant
concentrations. This finding was surprising because the lls, approximately 400 nm in
diameter, are much larger than what tional understanding sets as the upper limit of
12 nm for a particle that is able to cross the blood brain barrier (BBB). See Sarin et a].
(2008) and Laquintana et a1. (2009).
Accordingly, the inventors determined that a wide variety of brain tumors, both
primary and metastatic, can be treated by administering systemically a therapeutically
ive amount of a composition comprised of a plurality of such minicclls, each minicell
being a vehicle for an active agent t the tumor.
(A) Definitions
Unless defined otherwise, all technical and scientific terms used in this description
have the same g as commonly understood by those skilled in the relevant art.
] For convenience, the meaning of certain terms and phrases employed in the
specification, examples, and appended claims are ed below. Other terms and phrases
are defined throughout the specification.
The singular forms “a,” “an,3’ and “the” include plural reference unless the context
clearly dictates otherwise.
“Cancer,” “neoplasm,” “tumor,” “malignancy” and “carcinoma,” used
hangeably herein, refer to cells or tissues that exhibit an aberrant growth phenotype
characterized by a significant loss of l of cell proliferation. The methods and
compositions of this disclosure particularly apply to malignant, pre-metastatic, metastatic,
and non-metastatic cells.
I0034] “Drug” refers to any logically or pharmacologically active nce that
produces a local or systemic effect in s, particularly mammals and humans.
PCT/[82012/002950
“Individual,” “subject,” " and “patient,” terms used hangeably in this
description, refer to any mammalian subject for whom diagnosis, treatment, or therapy is
desired. The individual, subject, host, or patient can be a human or a non-human animal.
Thus, suitable subjects can include but are not limited to non-human primates, cattle, horses,
dogs, cats, guinea pigs, s, rats, and mice.
The terms “treatment,” ing, )’ 6‘treat,” and the like refer to obtaining a desired
pharmacological and/or physiologic effect in a brain tumor patient. The effect can be
prophylactic in terms of completely or partially preventing brain tumor or symptom thereof
and/or can be eutic in terms of a partial or complete stabilization or cure for brain
tumor and/or adverse effect attributable to the brain tumor. ent covers any treatment
of a brain tumor in a mammal, particularly a human. A desired , in particular, is tumor
response, which can be measured as reduction of tumor mass or inhibition of tumor mass
increase. In addition to tumor response, an increase of overall survival, progress-free
survival, or time to tumor ence or a reduction of adverse effect also can be used
clinically as a desired treatment effect.
(3) Treatments
The present disclosure is reflected in and substantiated by mental evidence that,
in keeping with the inventors’ discovery, bacterially derived and intact minicells, which are
about 400 nm in diameter, upOn intravenous (iv) administration accumulate rapidly in the
brain tumor microenvironment in eutically significant concentrations. The inventors
also discovered that this brain tumor penetration does not rely on BBB endothelial
endocytosis/transcytosis or on any of the other mechanism by which it has been proposed that
nanoparticles enter into the brain tumor microenvironment. From the vantage of
conventional knowledge, therefore, these eries were quite unexpected.
1. Conventional Knowledge About a Size Limitfor Crossing the BBB
Nanoparticles have been considered as potential carriers for taking drugs past the
BBB (Juillerat-Jeanncret, 2008). Illustrative in this regard is a nanoparticulate drug delivery
strategy aimed at ming by binding of nanoparticles to receptors in the lumen of
endothelial cells that comprise the BBB, followed by endocytosis and transcytosis across
endothelial cells and into the brain tumor microenvironment. r approach involves
PCT/[32012/002950
exploiting an “enhanced permeation and retention effect,” discussed below, to effect passage
of particles through tiny gaps between the endothelial cells of the BBB.
2. ytosis ofnanopartic/es
Poly(butyl cyanoacrylate (PBCA) nanoparticles coated with polysorbate 80 (Tweenfk:
80) were shown to enable brain delivery ofa number of drugs that did not cross the BBB in
free form (Kreuter er a/., 1995, 1997, 2001, 2002, 2003, and 2008; Steiniger et al., 2004).
Since rbatc 80 selectively es adsorption of certain plasma proteins (in
particular, apolipoproteins E and B, (Petri et al., 2007; Re 6! al., 201 1) on the surface of these
nanoparticles, it enables the binding of these nanoparticles with the tive low-density
lipoprotein receptors (LDLr; Xin er (1]., 201 l) which are known to be over-expressed in
endothelial blood capillary vessels associated with the BBB ck er al., 1994).
] Post-binding to the LDLr, the nanoparticles are internalized by the blood vessel
endothelial cells (Zensi et a/., 2009), transcytosed across these cells and then transported into
the brain tumor microenvironment.
A worldwide effort to develop rticles for treating brain tumors is focused on
finding innovative ways to se the BBB by transcytosing the BBB—associated cndothclial
cells and entering into the brain tumor microenvironment. This is a major challenge by virtue
of the fact that these particles must remain intact during the transcytosic intracellular
movement and not be degraded by lysosomes. The latter are highly acidic intracellular
compartments, which normally degrade endocytosed materials.
An additional s drawback of this approach is the fact that the LDLr is not
unique to the BBB. It is only over-expressed in the endothelial cells associated with the
BBB. Therefore, these nanoparticles have the ial to enter into a large number of normal
tissues and the normal central nervous system since these receptors are ubiquitously located
in endothelial cells throughout the circulatory system. So far, receptors have not been found
that are unique only to the BBB associated blood vessels and hence the potential for serious
ty to normal tissues remains a concern.
PCT/[B2012/002950
3. Passive entry into brain tumors
Recent evidence has indicated that the physiologic upper limit of pore size in the BBB
of malignant glioma microvasculature is only about 12 nm (Sarin er al., 2008). Further, it has
been shown that molecules would need to be as small as <400 Daltons (Bickcl, 2005;
Pardridge, 2007) to be able to cross the pores found in the BBB.
The sizing aints are widely accepted among researchers and ians in the
field. For instance, a review of the recent literature concluded that nanoparticles need to be
smaller than 12 nm and have long blood half-lives to cross the BBB of malignant glioma
microvasculature (Laquintana et al. , 2009).
A variety of nanoparticles have been studied in this regard, including liposomes,
polymeric nanopartieles, solid lipid nanoparticles, polymeric micelles, and dendrimers.
Following intravenous administration, these particles can extravasate into brain tumor,
because of the disrupted BBB of brain tumor vessels, but also to a lesser extent into normal
brain tissue as well (Moghimi et al., 2005).
This passive targeting of nanoparticles in brain tumors with disrupted BBB generally
is linked to the above-mentioned enhanced permeability and retention (EPR) effect, which is
deemed to play a al role in drug delivery to solid tumors. For instance, tana ct a].
(2009) reflects the current view that liposomes, which typically range between 50 to 150 nm,
remain within the microvasculature, whereby encapsulated small chemotherapy drugs diffuse
across the liposome membrane and across the pores with the BBB of malignant gliomas.
Thus, larger particles (50 to 150 nm) are not thought to be able to extravasate through the
BBB via disruptions in the bam'cr.
The tional understanding ore is that, in order to cross the BBB passively
via the EPR effect and to reach pharmacologically cant amounts in the brain tumor
nvironment, nanoparticles should be < 12 nm in size and macromolecules such as
drugs should have a molecular weight of < 400 Daltons. This understanding is underscored
in a review article by Pardridge (2010), which izes that the “single most important
factor in brain drug development is the availability of an effective brain drug targeting
technology.”
PCT/[32012/002950
This is e the majority of candidate drugs for the central nervous
system (CNS) do not cross the bloodbbrain barrier (BBB).
Biophamiaceuticals, which are large molecule drugs, do not cross the
BBB. Therefore, in the absence of brain targeting technology,
recombinant proteins, monoclonal antibodies, peptides, short
interfering RNA (siRNA), and gene therapeutics cannot be developed
for the brain, because these drugs do not cross the BBB. With t
to small les, it is generally assumed that these agents do cross
the BBB. However, >98% of all small molecules do not cross the BBB
(Pardridge et al., 2005). Only lipid soluble small molecules with a
lar weight (MW) <400 Daltons (Da) cross the BBB via lipid-
mediation. However, the majority of small molecule drugs either have
a MW >400 Da, or have high water solubility, which prevents free
diffusion through the BBB. ore, even if the CNS drug per
is focused on small molecules, it is likely that a BBB drug targeting
technology will still be required for successful completion of the CNS
small molecule drug development m for most drugs.
4. Additional barriers to brain tumor entry
Besides the BBB, brain uptake is further restricted by a relative paucity of fenestrae
and pinocytotic vesicles within the brain capillary endothelial cells, as well as by the presence
of the surrounding extracellular matrix, pericytes, and astrocyte foot processes (Hawkins and
Davis, 2005). Additionally, the BBB conventionally is deemed nable to drugs and
macromolecules by virtue of us drug transport ns, which move drugs out of the
brain.
For example, it has been shown that ATP-dependent transporters can severely restrict
the brain penetration of therapeutic agents, even those with favorable physicochemical
properties that were predicted to cross the BBB with relative ease. Most of these transporters
belong to two amilies, the ATP-binding cassette (ABC) and solute carrier families. P-
glycoprotein (P-gp, ABCBI), breast-cancer—resistance protein (BCRP, ABCGZ), and
multidrug resistance associated proteins (MRPs, ABCCs) are important members of the ABC
family. Sec Schinkel (1999), Borst et al. (2000), Sun et al. , Schinkel and Jonkcr
(2003), Kusuhara and Sugiyama (2005), Loscher and Potschka (2005), and Nicolazzo and
Katneni (2009).
Accordingly, the present inventors found it truly surprising that intact, bacterially
derived lls late in brain tumors, despite the fact that the minieells are
considerably larger (~ 400 nm) than the consensus upper size limit (< 12 nm) for
W0 2013/088250 PCT/[82012/002950
nanoparticles to enter into brain tumors. Also unexpected was the finding that minicells enter
the brain passively, via disrupted BBB. In this regard the inventors made the surprising
ation that blood vessels associated with brain tumors are not only of the BBB-type.
Even at an early stage, a growing tumor, it was found, has many blood vessels, particularly at
its core. Such blood vessels display a loss of integrity; that is, the vessels have large
fenestrations and are ,” unlike BBB-type vessels. In contravention of conventional
understanding, therefore, particles that are as large as minicells, 126., much larger than the
above-discussed consensus pore size tions of the BBB, heless are smaller than the
fenestrations in the walls of the leaky blood vessel; hence, they can extravasate passively
through these fenestrations and into the brain tumor microcnvironment.
Moreover, the inventors found that the relatively large size of , ially
derived minicells actually is a positive, even key factor in how rapidly therapeutically
significant minicells concentrations are achieved in the brain tumor microenvironment,
pursuant to the finding. The smaller the particle, that is, the more likely it is that the particle
will be ined by blood flow in blood vessels. By contrast, minicells are particles of a
relatively larger mass, and they therefore are less affected by the force exerted by blood flow.
Consequently, lls are more likely to follow a path through blood capillaries that results
in repeated collision against the endothelial walls of blood aries, This purely physical
enon increases the likelihood that minicells, as larger particles, are pushed through
the fenestrations in leaky vasculature that, as the inventors discovered, is the hallmark of the
disrupted BBB in tumors.
There are more than 100 billion capillaries in the human brain, presenting a total
length of approximately 400 miles, and yet the intra-endothelial volume of these capillaries is
only about 1 uL/g brain (Pardridge, 20l 1). This very high density of blood vessels in the
brain is believed also to contribute to the rapid, high-concentration accumulation of minicells
in brain tumors, ing to the finding.
izing that the diameter of the capillary lumen associated with the BBB thus
can be as small as 1 pm, the inventors had the insight that particles as large as intact,
ially derived minicells (~ 400 nm) would be about half the diameter of BBB-associated
blood capillary vessels and therefore would extravasate rapidly from disrupted BBB, where
gaps are greater than 400 nm in size. On the other hand, because fenestrations in the normal
PCT/lB2012/002950
ature of the mammalian body do not exceed about 100 pm in size, intact, bacterially
derived minicells that are introduced systemically, pursuant to the , are retained in the
general vascular system until they are scavenged up by professional phagocytic cells in the
reticuloendothelial system or until they passively extravasate from the leaky vasculature into
the brain tumor nvironment.
Accordingly, when two types of nanoparticles i.v. administered in equal numbers,
e.g., nanoparticles of less than 12 nm in diameter and intact, ially derived minicells,
then one would expect that the circulating concentration of the smaller particles would
decrease y, since they would extravasate out of the blood circulation in normal tissues,
where the vasculature has pores larger than 12 nm. It is known, for instance, that liver and
gastrointestinal tissue has normal vasculature fenestrations of about 100 nm (Wisse et (21.,
2008), and the peripheral skin has fenestrations in the range of ~40 nm. By contrast, the
minicells would be too large to fall out of the normal vasculature; hence, they would be
ed to stay in high concentration in the normal blood circulation, whereby greater
numbers would extravasate into the brain tumor microenvironment, as described above.
In accordance with one embodiment, therefore, the present disclosure provides a
treatment for a brain tumor that s administering a therapeutically effective amount of a
composition comprised of a ity of intact, ially derived minicells carrying an anti-
neoplastic agent. The administration of the minicell-containing composition preferably is
systemic, e.g., intravenous or intra-arterial.
(C) Anti-Neoplastic Agents
[0057} As noted, the miniecll compositions of the present disclosure are useful in delivering
anti-neoplastic agents to the brain tumors. In this context, the phrase “anti-neoplastic agent”
denotes a drug, whether chemical or biological, that prevents or inhibits the growth,
development, maturation, or spread of neoplastic cells.
In the context of this disclosure, selecting an eoplastic agent for treating a given
brain tumor patient s on several factors, in keeping with conventional medical
practice. These factors include but are not d to the patient’s age, Kamofsky Score, and
whatever previous therapy the patient may have received. See, generally, PRINCIPLES AND
PCT/[B2012/002950
PRACTICE or NEURO-ONCOLOGY, M. Mchta (Demos Medical Publishing 201 l), and
PRINCIPLES OF NEURO-ONCOLOGY, D. Schiff and P. O’Neill, eds. (McGraw-Hill 2005).
More generally, the standard of care applicable to a given brain cancer recommends,
in the first ce, the al considerations that should inform the choice of active agent
to use. This perspective would guide the selection, for example, of an active agent from a
list, uced below in Table 1, which the University of California at Los Angeles has
published of anti-neoplastic agents that are suitable for treating brain tumors.
Table 1. Known anti-neoplastic agents for ng brain tumors
Gcnetech
Cilenitide (EMD 121974)
Etoposidc (Eposin. Elopophos, GDC-0449
Vecsid)
Glcevec (imalinib mes late) GLIADEL Wafer H drox chloro uinc
IL—13 IMC-3G3
Ircssa ZD 18" La atinib GW572016)
Melholrexatc for Cancer (5 slemic
PCV Proearbazine RADOO! Novartis (mTOR inhibitor)
SU-lOl SUS4l6 SII-en Sulfasalazine (Azulfidine)
Sulent (Pfizer) Tamoxifen TARCEVA (erlotinib HCl
Taxol TEMODAR Scherin--Plou li TGF-B Anti-Sense
Thalomid (thalidomide) To olecan (S )
In accordance with the disclosure, a drug also can be selected from one of the classes
detailed below, for ing into intact, bacterially derived lls, which then are
administered to treat a brain cancer.
0 Polyfunctional alkylating agents, exemplified by Cyclophosphamide (Cytoxan),
Mechlorethamine, Melphalan (Alkeran), mbucil (Leukeran), Thiopeta (Thioplex),
Busulfan (Myleran).
PCT/[82012/002950
Alkylating drugs, exemplified by Procarbazine (Matulane), Dacarbazine (DTIC),
Altrctaminc (Hexalcn), Clorambucil, Cisplatin (Platinol), Carboplatin, lfosafamidc,
Oxaliplatin.
tabolites, exemplified by Methotrexate (MTX), 6-Thiopurines (Mercaptopurine
, Thioguanine [6-TG]). Mercaptopurine (Purinethol), anine, Fludarabine
phosphate, Cladribinc: (Leustatin), Pentostatin, Flurouracil (S-FU), Cytarabine (ara-C),
Azacitidinc.
Plant alkaloids, terpenoids and topoisomerase inhibitors, exemplified by Vinblastine
(Velban), stine (Oncovin), Vindesine, Vinorelbine, Podophyllotoxins (etopOSide
{VP- 16}and teniposide {VM-26}), Camptothecins (topotecan and irinotccan ), Taxanes
such as Paclitaxel (Taxol) and Docetaxel (Taxotere).
Antibiotics, exemplified by bicin (Adriamycin, Rubex, Doxil), Daunorubicin,
ldambicin, Dactinomycin (Cosmcgcn), Plicamycin (Mithramycin), cin:
(Mutamycin), Bleomycin (Blenoxane).
Hormonal agents, exemplified by en and Androgen Inhibitors (Tamoxifen and
Flutamide), Gonadotropin-Releasing Hormone Agonists (Leuprolide and Goserelin
(Zoladex)), Aromatase tors (Aminoglutethimide and Anastrozole (Arimidex)).
laneous Anticancer Drugs, exemplified by Amsacrine, Asparaginase (El-spar),
Hydroxyurea, Mitoxantrone (Novantrone), Mitotane (Lysodren), Retinoic acid
Derivatives, Bone Marrow Growth Factors (sargramostim and tim), Amifostine.
Agents disrupting folate metabolism, e.g., Pemetrexed.
DNA hypomethylating agents, e.g., idine, bine.
Poly(adenosine diphosphate [ADPl-ribose) polymerase (PARP) pathway inhibitors,
such as Iniparib, Olaparib, Vcliparib.
Pl3K/Akt/mTOR y inhibitors, e. g., Everolimus.
PCT/lB2012/002950
- Histone deacetylase (HDAC) inhibitors, e.g., Vorinostat, Entinostat (SNDX-275),
Mocetinostat 103), Panobinostat (LBHS 89), Romidepsin, Valproic acid.
0 Cyclin-dependent kinase (CDK) inhibitors, e.g., Flavopiridol, Olomoucine,
Roscovitine, Kenpaullone, AG-024322 (Pfizer), Fascaplysin, Ryuvidine, Purvalanol A,
NU2058, BML-259, SU 9516, PD-0332991, P276—00.
0 Heat shock protein (HSP90) inhibitors, e.g., Geldanamycin, Tanespimycin,
Alvespimycin, col, Deguelin, B11B02l.
o Murine double minute 2 (MDMZ) tors, e.g., Cis-imidazoline,
Benzodiazepinedione, oxindoles, Isoquinolinone, ene, 5-Deazaflavin,
minc.
o Anaplastic lymphoma kinase (ALK) inhibitors, e.g., Aminopyridine,
Diaminopyrimidine, Pyridoisoquinoline, Pyrrolopyrazole, lndolocarbazole,
Pyrrolopyrimidine, Dianilinopyrimidine.
o Poly [ADPribose] polymerase (PARP) inhibitors, illustrated by Benzamide,
Phthalazinone, Tricyclic indole, Benzimidazole, le, Pyrroiocarbazole,
Phthalazinone, Isoindolinone.
Active agents useable in the present disclosure are not limited to those drug classes or
particular agents enumerated above. Different discovery platforms continue to yield new
agents that are directed at unique lar signatures of cancer cells; indeed, thousands of
such chemical and biological drugs have been discovered, only some of which are listed here.
Yet, the surprising capability of intact, ially derived lls to accommodate
packaging of a diverse variety of active agents, hydrophilic or hydrophobic, means that
essentially any such drug, when packaged in minicells, has the potential to treat a brain
, pursuant to the findings in the present disclosure.
In principle, the potential suitability of a given anti-neoplastic agent for treating a
brain tumor is partly a function of whether the agent can be delivered effectively into the
brain. With the benefit of the present findings, whereby drug-loaded minicclls traverse the
BBB and deliver a drug d into a brain tumor specifically, many drugs that otherwise
PCT/[82012/002950
would not have proven efficacious in treating a brain tumor now will be viable candidates for
such treatment. Accordingly, in this description the “anti-neoplastic agent” rubric is not
limited to drugs of known efficacy for brain cancer therapy, but also rather it encompasses
agents that are ined to have one or more of the aforementioned activities against
neoplastic cells.
Likewise illustrative of the class of anti-neoplastic agents are radionuclides,
chemotherapy drugs, and functional nucleic acids, including but not limited to regulatory
RNAs.
1. Radionuclides
A “radionuclide” is an atom with an unstable nucleus, [.0, one characterized by
excess energy available to be imparted either to a newly created radiation particle within the
nucleus or to an atomic electron. ore, a radionuclide undergoes radioactive decay, and
emits gamma ray(s) and/or subatomic particles. Numerous radionuclides are known in the
art, and a number of them are known to be le for medical use, such as yttrium-90,
technetium-99m, iodine—123, iodine-131, rubidium-82, um-201, gallium-67, fluorine-18,
xenon-133, and indium-l ] l.
Radionuclides have found extensive use in r medicine, ularly as beta-ray
emitters for damaging tumor cells. Radionuclides are suitably employed, therefore, as anti-
neoplastic agents in the present disclosure.
Radionuclides can be associated with intact, ially derived minicells by any
known que. Thus, a protein or other minicell—surface moiety (see below) can be
labeled with a radionuclide, using a commercially available labeling means, such as use of
Pierce lodination reagent, a product of Pierce Biotechnology lnc. (Rockford, IL), detailed in
Rice et al. (2011). Alternatively, uclides can be incorporated into proteins that are
inside minicells.
In the latter ion, a minicell-producing bacterial strain is transformed with
plasmid DNA encoding foreign protein. When minicells are formed during asymmetric cell
division, several copies of the plasmid DNA segregates into the minicell asm. The
resultant, recombinant minicells are incubated, in the presence of radiolabeled amino acids,
under conditions such that foreign protein expressed inside the minicell, from the plasmid
PCT/[82012/002950
DNA, incorporates the uclide-carrying amino acids. Pursuant to the protocol of Clark-
Curtiss and Curtiss (1983), for instance, recombinant minicells are incubated in minimal
growth medium that contains 3’SS-methionine, whereby newly expressed, plasmid-encoded
proteins incorporate the 3SS-methionine. A similar approach can be used in order that
recombinant minicells become packaged with other abels, as desired.
Oligosaccharides on the minicell surface also can be radiolabeled using, for example,
well-established protocols described by Fukuda (1994). Illustrative of such oligosaccharides
that are endemic to lls is the O-polysaccharide component of the lipopolysaccharide
(LPS) found on the surface of minicells derived from Gram-negative bacteria (see below).
A preferred methodology in this regard is to radiolabel a bispccific antibody that is
used to target minicells to ic . See section G, z'nfl‘a, and patent publication
US 2007/0237744, the contents of which are incorporated herein by reference. That is, the
bispecific antibody “coated” on a miniccll exposes a significant amount of additional surface
protein for radiolabeling. Accordingly, it is possible to achieve a higher ic activity of
the radiolabel associated with the antibody-coated minicell. By contrast, the radiolabeling of
non-coated minicells, i.e., when the radionuclide labels only endemic moieties, can result in
weaker labeling (lower specific activity). In one embodiment, this weaker labeling is thought
to occur because the outer membrane-associated proteins of minicells derived from Gram-
negative ia are masked by LPS, which, as r discussed below, comprises long
chains of O—polysaccharide covering the minicell surface.
For treating a brain tumor, a composition of the disclosure would be delivered in a
dose or in le doses that in toto affords a level of in-tumor irradiation that is sufficient at
least to reduce tumor mass, if not eliminate the tumor altogether. The progress of treatment
can be monitored along this line, on a case-by-case basis. In general terms, r, the
amount of radioactivity packaged in the composition typically will be on the order of about
to 50 Gy, gh the invention also plates a higher amount of ctivity, say,
about 50 to 100 Gy, which gives an l range between about 30 Gy and about 100 Gy.
In some instances the amount of radioactivity packaged in the composition can be
even lower than mentioned above, given the highly efficient and specific delivery of the
minicell-born uclides to a brain tumor. Accordingly, in one aspect the composition
PCT/[82012/002950
ns from about 20 to 40 Gy, or about 10 to 30 Gy, or about 1 to about 20 Gy, or less
than 10 Gy.
2. Chemotherapy Drugs
An anti-neoplastic agent employed in the present disclosure also can be a
herapy drug. In this description, “chemotherapeutic drug, 7, tschemotherapeutic agent,”
and “chemotherapy” are employed interchangeably to connote a drug that has the ability to
kill or disrupt a stic cell. A chemotherapeutic agent can be a small molecule drug or a
ic drug, as further detailed below.
The “small molecule drug” subcategory encompasses organic compounds
characterized by having (i) an effect on a ical process and (ii) a relatively low
molecular , compared to a oleeule. Small molecule drugs typically are about
800 Daltons or less, where “about” indicates that the qualified molecular-weight value is
subject to variances in measurement precision and to experimental error on the order of
several Daltons or tens of Daltons. Thus, a small molecule drug can have a molecular weight
of about 900 Daltons or less, about 800 or less, about 700 or less, about 600 or less, about
500 or less, or about 400 Daltons or less. More cally, a small molecule chemotherapy
drug can have a molecular weight of about 400 Daltons or more, about 450 Daltons or more,
about 500 Daltons or more, about 550 Daltons or more, about 600 Daltons or more, about
650 Daltons or more, about 700 Daltons or more, or about 750 Daltons or more. In r
embodiment, the small molecule chemotherapy drug packaged into the minicelis has a
molecular weight between about 400 and about 900 Daltons, between about 450 and about
900 Daltons, between about 450 and about 850 Daltons, between about 450 and about 800
Daltons, between about 500 and about 800 Daltons, or between about 550 and about 750
Daltons.
For es of this description a “biologic drug” is defined, by contrast, to denote
any ically active macromolecule that can be created by a biological process, exclusive
of “functional nucleic acids,” discussed below, and polypeptides that by size y as small
molecule drugs, as defined above. The “biologic drug” subcategory thus is exclusive of and
does not overlap with the small molecule drug and functional nucleic acid subcategories.
Illustrative of biologic drugs are therapeutic proteins and antibodies, whether natural or
PCT/[32012/002950
recombinant or synthetically made, e.g., using the tools of medicinal chemistry and drug
design.
It was widely understood heretofore that molecules larger than 400 Daltons would be
unable to cross the pores found in the BBB (Bickcl, 2005; Pardridgc, 2007); hence, that they
would be able for treating brain tumors. When packaged into minicells, however, such
chemotherapy drugs reaching targeted brain tumor cells, bypassing the BBB.
Whether a small molecular drug or a biologic drug, moreover, certain molecules that
are designed for chemotherapeutic purposes nevertheless fail during pre-clinieal or clinical
trials due to unacceptable ty or other safety concerns. The present inventors have
shown that ing a chemotherapy drug in a minicell, ed by systemic delivery to a
tumor patient, such as a brain tumor patient, results in ry of the drug to tumor cells.
Further, even after the tumor cells are broken up and the ontaining cytoplasm is
released to the nearby normal tissue, the result is not toxicity to normal tissue. This is
because the drug is already bound to the tumor ar structures, such as DNA, and can no
longer attack normal cells. Accordingly, the present invention is particularly useful for
delivery of highly toxic chemotherapy drugs to a tumor patient.
The s “highly toxic chemotherapy drug” or “supertoxie chemotherapy drug” in
this description refer to chemotherapy drugs that have a relative low lethal dose as compared
to their effective dose for a targeted cancer. Thus, in one aspect a highly toxic chemotherapy
drug has a median lethal dose (LDso) that is lower than its median effective dose (ED50) for a
targeted cancer such as (1) a cancer type for which the drug is designed, (2) the first cancer
type in which a pre-clinical or clinical trial is run for that drug, or (3) the cancer type in which
the drug shows the highest efficacy among all tested cancers. For instance, a highly toxic
chemotherapy drug can have an LD50 that is lower than about 500%, 400%, 300%, 250%,
200%, 150%, 120%, or 100% of the ED50 of the drug for a targeted cancer. In another
aspect, a highly toxic chemotherapy drug has a maximum sub-lethal dose (i.e., the highest
dose that does not cause serious or irreversible toxicity) that is lower than its minimum
effective dose for a targeted cancer, e.g., about 500%, 400%, 300%, 250%, 200%, 150%,
120%, 100%, 90%, 80%, 70%, 60% or 50% ofthe minimum effective dose.
PCT/132012/002950
According to one embodiment of the present description, therefore, a brain tumor in a
subject is treated by a method comprising administering systemically a eutically
effective amount of a composition comprised of a plurality of intact, bacterially derived
minicells, each of which encompasses a highly toxic chemotherapy drug. Maytansinoids and
duocarmycins, discussed below, are representative of the class of supertoxie chemotherapy
drugs thus employed.
Suitable cancer chemotherapy drugs in the context include nitrogen mustards,
nitrosorueas, ethyleneimine, alkane sulfonates, tetrazine, platinum compounds, pyrimidine
analogs, purine s, antimetabolites, folate analogs, anthracyclines, taxanes, vinca
alkaloids, topoisomcrase inhibitors, and hormonal agents, inter alia.
Chemotherapy drugs that are illustrative of the small le drug subcategory are
Actinomycin-D, Alkeran, Ara-C, Anastrozole. BiCNU, Bicalutamide, Bleomycin, Busulfan,
Capecitabine, Carboplatin, Carboplatinum, Carmustine, CCNU, Chlorambueil, Cisplatin,
Cladribine, CPT-ll, Cyclophosphamide, Cytarabine, Cytosine arabinoside, Cytoxan,
azine, omycin, Daunorubicin, Dexrazoxane, Docetaxel, Doxorubicin, DTlC,
Epirubicin, Ethyleneimine, Etoposide, Floxuridine, Fludarabine, Fluorouracil, Flutamide,
stine, Gemcitabine, Hexamethylamine, Hydroxyurea, Idarubicin, Ifosfamide,
ecan, ine, Mechlorethamine, Melphalan, topurine, Methotrexate,
Mitomycin, Mitotane, ntrone, Oxaliplatin, Paclitaxel, Pamidronate, tatin,
Plicamyein, Procarbazine, Steroids, Streptozocin, STl-57l, Streptozocin, Tamoxifen,
lomide, side, Tetrazine, Thioguanine, Thiotepa, x, Topotecan,
Treosulphan, Trimetrexate, Vinblastine, Vincristine, Vindesine, Vinorelbine, VP-l6, and
Xcloda.
Maytansinoids (molecular weight: ~738 Daltons) are a group of chemical derivatives
of maytansine, having potent cytotoxicity. Although considered unsafe for human patient
use, due to toxicity concerns, maytansinoids are suitable for delivery to brain tumor patients
via minieells, pursuant to the present invention.
Duocarrnycins (molecular weight: ~588 Daltons) are a series of related natural
products, first isolated from omyces ia. They also have potent cytotoxicity but
are considered as unsafe for human use. Like maytansinoids, duocarrnycins are suitable
chemotherapy drugs for use in the invention.
The subcategory of biologic chemotherapy drugs includes, without limitation,
Asparaginasc, AIN-457, Bapincuzumab, Bclimumab, ximab, Briakinumab,
Canakinumab, Cetuximab, Dalotuzumab, Denosumab, Epratuzumab, Estafenatox,
Farletuzumab, Figitumumab, Galiximab, Gemtuzumab, Girentuximab (WX-GZSO),
Herceptin, Ibritumomab, umab, Ipilimumab, Mepolizumab, Muromonab-CD3,
Naptumomab, Necitumumab, Nimotuzumab, Oerelizumab, Ofatumumab, Otelixizumab,
Ozogamicin, Pagibaximab, Panitumumab, Pertuzumab, Ramucirumab, Reslizumab,
Rituximab, REGNSS, Solanezumab, Tanezumab, Teplizumab, Tiuxetan, Tositumomab,
Trastuzumab, Tremelimumab, Vedolizumab, Zalutumumab, and Zanolimumab.
The composition can contain at most about 1 mg of the chemotherapeutic drug.
Alternatively, the amount of the chemotherapeutic drug can be at most about 750 pg, 500 ug,
250 pg, 100 ug, 50 pg, 10 pg, 5 pg, 1 ug, 0.5ug, or 0.1 pg. In another aspect, the
composition contains a chemotherapeutic drug having an amount of less than about l/l,000,
or alternatively less than about 1/2,000, 0, 1/10,000, l/20,000, 0, 1/100,000,
000 or 000 of the therapeutically effective amount of the dmg when used t
being packaged to into minicells. Pursuant to yet another aspect of the disclosure, the
composition can c0ntain at least about 1 nmol of the chemotherapeutic drug. Accordingly,
the disclosure also encompasses embodiments where the amount of the chemotherapeutic
drug is at least about 2 nmol, about 3 nmol, about 4 nmol, about 5 nmol, about 10 nmol,
about 20 nmol, about 50 nmol, about 100 nmol, and about 800 nmol, respectively.
3. Functional Nucleic Acids
ional nucleic acid” refers to a nucleic acid le that, upon introduction
into a host cell, specifically interferes with expression of a protein, With respect to treating a
brain tumor, in accordance with the disclosure, it is able that a onal nucleic acid
payload delivered to tumor cells via intact, bacterially derived minicells inhibits a gene that
promotes tumor cell eration, angiogenesis or resistance to chemotherapy and/or that
inhibits apoptosis or cell-cycle arrest (i.e., a “tumor-promoting gene”).
PCT/[B2012/002950
It is generally the case that functional nucleic acid molecules used in this disclosure
have the capacity to reduce expression of a protein by interacting with a ript for a
protein, This category of minicell payload for the disclosure includes regulatory RNAs, such
as siRNA, shRNA, short RNAs (typically less than 400 bases in ), micro-RNAs
(miRNAs), ribozymes and decoy RNA, antisense nucleic acids, and LineRNA, inter alia. In
this regard, “ribozyme” refers to an RNA molecule having an enzymatic activity that can
repeatedly cleave other RNA molecules in a nucleotide base sequence-specific manner.
“Antisense oligonucleotide” denotes a nucleic acid molecule that is complementary to a
portion of a particular gene transcript, such that the molecule can hybridize to the transcript
and block its translation. An antiscnsc oligonucleotide can comprise RNA or DNA. The
“LincRNA” or “long intergcnic non-coding RNA” rubric asses non~protein coding
transcripts longer than 200 nucleotides. LincRNAs can regulate the transcription, splicing,
and/or translation of genes, as sed by Khalil et al., Proc Nat ’l Acad. USA 106: 11667—
72 (2009), for instance.
Each of the types of regulatory RNA can be the source of onal nucleic acid
molecule that inhibits a tumor-promoting gene as bed above and, hence, that is suitable
for use according to the present disclosure. Thus, in one preferred embodiment of the
disclosure the intact minicells carry siRNA molecules mediating a post~transcriptional, gene-
silencing RNA interference (RNAi) mechanism, which can be exploited to target tumor-
promoting genes. For example, see MacDiarmid er al., Nature Biotech. 27: 645-51 (2009)
(antibody-presenting minicells deliver, with chemotherapy drug, siRNAs that counter
developing ance to drug), and Oh and Park, Advanced Drug ry Rev. 61: 850-62
(2009) (delivery of therapeutic siRNAs to treat breast, ovarian, al, liver, lung and
prostate cancer, respectively).
As noted, “siRNA” generally refers to double-stranded RNA molecules from about 10
to about 30 nucleotides long that are named for their y specifically to interfere with
n expression. Preferably, siRNA les are 12-28 nucleotides long, more
preferably 15-25 nucleotides long, still more preferably 19-23 nucleotides long and most
preferably 21-23 nucleotides long. Therefore, siRNA molecules can be 12, 13, 14, 15, 16,
17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27 28 or 29 nucleotides in length.
W0 2013/088250 2012/002950
The length of one strand designates the length of an siRNA molecule. For instance,
an siRNA that is described as 21 ribonucleotides long (a 21-mer) could comprise two
opposing s of RNA that anneal for 19 contiguous base pairings. The two remaining
ribonucleotides on each strand would form an “overhang.” When an siRNA contains two
strands of different lengths, the longer of the strands designates the length of the siRNA. For
instance, a dsRNA containing one strand that is 2| nucleotides long and a second strand that
is 20 nucleotides long, constitutes a 21-mer.
Tools to assist the design of siRNA cally and regulatory RNA generally are
readily available. For instance, a computer-based siRNA design tool is available on the
internet at www.dharmacon.com.
In another preferred embodiment, the intact minicells of the present disclosure carry
miRNAs, which, like siRNA, are e of mediating a post-transcriptional, gene-silencing
RNA interference (RNAi) mechanism. Also like siRNA, the ilencing effect mediated
by miRNA can be exploited to target tumor-promoting genes. For example, see Kota et a/.,
Cell 137: 1005-17 (2009) (delivery of a miRNA via transfection resulted in inhibition of
cancer cell proliferation, tumor-specific sis and dramatic protection from disease
progression without toxicity in murine liver cancer model), and Takeshita, et al., Melee.
Ther. 18: 181-87 (2010) (delivery of synthetic miRNA via ent ection inhibited
growth of metastatic prostate tumor cells on bone tissues).
Although both mediate RNA interference, miRNA and siRNA have noted differences.
In this , “miRNA” generally refers to a class of 17- to 27-nucleotide single-stranded
RNA molecules (instead of double-stranded as in the ease of siRNA). Therefore, miRNA
molecules can be l7, l8, 19, 20, 21, 22, 23, 24, 25, 26, 27 nucleotides in length. Preferably,
miRNA molecules are 21-25 nucleotide long.
Another difference between miRNAs and siRNAs is that the former generally do not
fully complement the mRNA target. On the other hand, siRNA must be completely
complementary to the mRNA target. Consequently, siRNA generally results in silencing of a
single, c target, while miRNA is promiscuous.
Additionally, although both are assembled into RISC (RNA-induced silencing
complex), siRNA and miRNA differ in their respective l processing before RISC
PCT/[B2012/002950
ly. These differences are described in detail in Chu et al., PLoS y 4: 1122-36
(2006), and Gregory et al., Methods in Molecular Biology 342: 33-47 (2006).
A number of databases serve as miRNA depositories. For example, see miRBase
(www.mirbase.org) and tarbase (http://diana.cslab.cee.ntua.gr'DianaToolchw/
index.php?r=tarbaserindex). In conventional usage, miRNAs typically are named with the
prefix “-mir,” combined with a sequential number. For instance, a new miRNA discovered
after mouse mir-352 will be named mouse mir-353.
Again, tools to aSSist the design of regulatory RNA including miRNA are readily
available. In this regard, a computer-based miRNA design tool is available on the intemet at
wmd2.weigelworld.org/cgi-bin/mimatoolspl.
As noted above, a functional nucleic acid employed in the disclosure can inhibit a
gene that promotes tumor cell eration, angiogenesis or resistance to herapy. The
inhibited gene also can itself inhibit apoptosis or cell cycle arrest. Examples of genes that
can be targeted by a functional nucleic acid are provided below.
Functional c acids of the sure preferably target the gene or transcript of a
protein that promotes drug resistance, inhibits apoptosis or es a neoplastic phenotype.
Successful application of functional nucleic acid strategies in these contexts have been
achieved in the art, but without the s of ll vectors. See, e.g., Sioud (2004),
Caplen (2003), Nieth et al. (2003), Caplen and Mousses (2003), Duxbury et al. (2004),
Yague et al. (2004), and Duan er al. (2004).
Proteins that contribute to drug resistance constitute preferred s of functional
nucleic acids. The proteins may contribute to acquired drug resistance or intrinsic drug
resistance. When diseased cells, such as tumor cells, initially respond to drugs, but become
refractory on subsequent treatment cycles, the resistant phenotype is acquired. Useful targets
involved in acquired drug resistance include ATP binding cassette orters such as P-
glycoprotein (P-gp, P-l70, PGYl, MDRl, ABCB], MDR-associated protein, Multidrug
resistance n 1), MDR-2 and MDR-3. MRP2 (multi-drug resistance associated protein),
BCR-ABL (breakpoint cluster region ‘ Abelson protooncogene), a STl-571 resistance-
associated protein, lung resistance-related protein, cyclooxygenase-2, nuclear factor kappa,
XRCCI (X-ray cross-complementing group I), ERCCI (Excision cross-complementing
WO 88250 PCT/[82012/002950
gene), GSTP] (Glutathione sfcrasc), mutant B-tubulin, and growth factors such as IL-6
are additional targets involved in ed drug resistance.
Particularly useful targets that bute to drug resistance include ATP binding
cassette transporters such as P-glyeoprotein, MDR-2, MDR-3, BCRP, APTI 1a, and LRP.
Useful targets also include proteins that promote apoptosis resistance. These include
Bel-2 (B cell leukemia/lymphoma), Bel-XL, Al/Bfl l, focal adhesion kinase, dihydrodiol
dehydrogenase, and p53 mutant protein.
Uscfiil targets further e oncogenic and mutant tumor suppressor proteins.
Illustrative of these are B-Catenin, PKC-a (protein kinasc C), C-RAF, K-Ras (V12), DP97
Dead box RNA helicase, DNMTI (DNA methyltransferase 1), FLIP (Flice-like inhibitory
n), C-Sfc, SBBPl, Polycomb group protein Ell-12 (Enhancer of zeste homologue),
ErbBl, HPV-16 E5 and E7 (human papillomavirus early 5 and early 7), Fortilin & MCIIP
(Mycloid cell ia 1 protein), DIP13a (DDC interacting protein 13a), MBD2 (Methyl
CpG binding domain), p21, KLF4 (Kruppel-like factor 4), tpt/TCTP (Translational controlled
tumor n), SPKl and SPK2 (Sphingosinc kinasc), P300, PLKl (Polo-like kinasc-l),
Trp53, Ras, ErbB], VEGF (Vascular endothelial growth factor), BAG-l (BCL2-associated
athanogene 1), MRPZ, BCR-ABL, ST1-571 resistance-associated protein, lung resistance-
d protein, cyclooxygenase-Z, nuclear factor kappa, XRCCl, ERCCI, GSTP], mutant [3-
tubulin, and growth factors.
{0103] Also useful as targets are global regulatory ts exemplified by the cytoplasmic
polyadenylation element g proteins ). For instance, CEPB4 is overexpressed in
glioblastoma and pancreatic cancers, where the protein activates hundreds of genes associated
with tumor growth, and it is not detected in healthy cells (Oritz-Zapater et al., 2011). In
accordance with the present description, therefore, treatment of a glioblastoma could be
effected via administration of a composition containing intact, bacterially derived minicells
that ass an agent that counters overexpression of CEPB4, such as an siRNA or other
functional nucleic acid molecule that disrupts CEPB4 expression by the brain tumor cells.
PCT/182012/002950
(D) Brain Tumors
The fact that loss of vascular integrity, as detailed above, is characteristic of all types
and stages of brain tumors means that methodology in ance with the present disclosure
can be adapted for use in treating any brain tumor. In this regard, “brain tumor” connotes a
solid neoplasm that is intracranial or in the central spinal canal.
There are more than 120 types of brain tumors. Most medical institutions use the
World Health Organization (WHO) classification system to identify brain tumors. The WHO
classifies brain tumors by cell origin and how the cells behave, from the least aggressive
(benign) to the most aggressive (malignant). Some tumor types are assigned a grade, ranging
From Grade 1 (least ant) to Grade IV (most malignant), which signifies the rate of
growth. There are variations in grading systems, depending on the tumor type. The
classification and grade of an individual tumor help predict its likely behavior. The most
frequently diagnosed types e acoustic neuroma, astrocytoma (including Grade I -
tic astrocytoma, Grade II - low-grade astrocytoma, Grade 111 - stie astrocytoma,
and Grade IV - glioblastoma (GBM)), ma, CNS lymphoma, craniopharyngioma, other
gliomas (brain stem glioma, ependymoma, mixed glioma, optic nerve glioma and
subependymoma), medulloblastoma, meningioma, atic brain tumors,
oligodendroglioma, ary tumors, primitive neuroectodermal (PNET), other brain-related
conditions, and schwannoma.
Among children, these brain tumor types are more common: brain stem glioma,
craniopharyngioma, ependymoma, juvenile pilocytic astrocytoma (JPA), medulloblastoma,
optic nerve glioma, pineal tumor, primitive neuroectodermal tumors (PNET), and rhabdoid
tumor.
The present technology can be applied to treating any brain tumor, ing but not
limited to the aforementioned types and grades, so long as angiogenesis has been red.
In practice, this benchmark pertains at least when a tumor is able by MRI, i.e., when it
has grown to a size such that new vascularisation is required. Thus, the inventive
methodology is suitable for ng a primary brain tumor or a metastatic secondary) brain
tumors, in any of the following stages:
PCT/132012/002950
Grade 1: The tissue is benign. The cells look nearly like normal brain cells, and cell
growth is slow.
Grade II: The tissue is malignant. The cells look less like normal cells than do the
cells in a grade 1 tumor.
Grade 111: The malignant tissue has cells that look very different from normal cells.
The abnormal cells are ly growing. These abnormal-appearing cells are termed
stic.
Grade IV: The malignant tissue has cells that look most abnormal and tend to grow
very fast.
Different tumor types are known to overexpress certain receptors on their cell surface.
For instance, breast cancers that metastasize to the brain tend to have a larger proportion of
metastatic breast cancer cells that overexpress HER2 receptor (Palmieri et a/., 2007). The
same authors showed that EGF receptor expression also is much higher in brain metastases.
In another example, the (13131 integrin or has been shown to be overexpressed in lung
cancer cells that have metastasized to the brain (Yoshimasu er a/., 2004).
So informed, a ent according to the present description of brain metastases
resulting from a particular primary cancer could be adapted accordingly to use a targeting
ligand, for the packaged minicells, that has a specificity appropriate to the primary
cancer. Thus, for brain metastases resulting from a primary breast cancer a treatment could
employ a ligand that exhibits HER2 specificity, with the ligand attached to the minicell.
Similarly, to treat brain metastases caused by primary lung cancer, the ligand would be one
that exhibits (1361 specificity, such as an anti- (136] antibody, and so on.
Pursuant to conventional logy, systemic stration of monoclonal
antibodies like anti-HER2, as in the Genentech product, trastuzumab, is understood
not to treat brain metastases resulting from primary breast cancer. This understanding stems
from the fact that antibody active agents do not cross the blood brain barrier effectively
enough to achieve therapeutically significant concentrations in the brain mestastatic tumor.
For example, see Stemmler er a]. (2007) (trastuzumab levels in cerebrospinal fluid increased
only under ions of an impaired blood-brain r, such as meningeal carcinomatosis
or radiotherapy). All the more surprising and significant, therefore, is the effectiveness of a
PCT/1820121002950
composition as described here to treat metastatic brain cancers, targeted by a ligand in the
aforementioned manner.
(E) Minicel/s
“Minicell” refers to a derivative of a bacterial cell that is lacking in chromosomes
(“chromosome-free”) and is engendered by a disturbance in the coordination, during binary
fission, of cell on with DNA segregation. Minicells are distinct from other small
vesicles, such as so-called “membrane blebs” (~ 0.2um or less in size), which are generated
and released spontaneously in certain situations but which are not due to specific genetic
rearrangements or episomal gene expression. By the same token, intact minicells are ct
from bacterial ghosts, which are not generated due to specific genetic rearrangements or
episomal gene expression. Bacterially derived minicells employed in this disclosure are fully
intact and, thus, are distinguished from other chromosome-free forms of bacterial cellular
derivatives characterized by an outer or defining ne that is ted or degraded,
even removed. See US. patent No. 7,183,105 at column 111, lines 54 er seq. The intact
ne that characterizes the minicells of the present disclosure allows retention of the
therapeutic payload within the minicell until the d is released, post-uptake, within a
tumor cell.
The minicell employed in this disclosure can be prepared from bacterial cells, such as
E. coli and S. typhymurium. Prokaryotic chromosomal replication is linked to normal binary
fission, which involves mid-cell septum formation. In E. 0011', for example, mutation of min
genes, such as minCD, can remove the inhibition of septum formation at the cell poles during
cell division, ing in production of a normal daughter cell and an some-less
minicell. See de Boer et al., 1992; Raskin & de Boer, 1999; Hu & Lutkenhaus, 1999; Harry,
200].
In addition to min operon mutations, chromosome-less minicells also are ted
following a range of other genetic rearrangements or mutations that affect septum formation,
for e, in the dileBl in B. subtilis. See Reeve and Comett (1975). Minicells also can
be formed following a perturbation in the levels of gene expression of proteins involved in
cell division/chromosome segregation. For instance, over-expression of minE leads to polar
division and production of lls. Similarly, chromosome-less minicells can result from
defects in chromosome segregation, e.g., the smc on in Bacillus subtilis (Britton er (1].,
1998), the spoOJ deletion in B. subtilis (Ireton er al., 1994), the mukB mutation in E. coli
(Hiraga er al., 1989), and the [MIC mutation in E. 0012' (Stewart and D‘Ari, 1992). Further,
CafA can enhance the rate of cell division and/or inhibit chromosome partitioning afier
replication (Okada et al., 1994), resulting in formation of chained cells and chromosome-less
minicells.
Accordingly, minicells can be prepared for the present disclosure from any bacterial
cell, be it of Gram-positive or Gram-negative origin. Furthermore, the minicells used in the
disclosure should possess intact cell walls (i.e., are “intact lls”), as noted above, and
should be distinguished over and ted from other small vesicles, such as ne
blebs, which are not attributable to specific genetic rearrangements or al gene
expression.
In a given embodiment, the parental e) ia for the minicells can be Gram
positive, or they can be Gram negative, as mentioned. In one aspect, therefore, the parental
ia are one or more selected from Terra-/Glidobaeteria (BV l), Proteobacteria (B V2),
BV4 including Spirochaetes, Sphingobacteria, and Planctobacteria. Pursuant to another
aspect, the bacteria are one or more selected from Firmicutes (BV3) such as Baeilli,
idia or Tenericutes/Mollicutes, or Actinobacteria (BVS) such as Aetinomycetales or
Bifidobacteriales.
In yet a further aspect, the bacteria are one or more selected from Eobacteria
(Chloroflexi, Deinococcus-Thermus), Cyanobacteria, Thennodesulfobacteria, thermophiles
(Aquificae, Thermotogae), Alpha, Beta, Gamma (Enterobacteriaceae), Delta or Epsilon
Proteobacteria, Spirochaetes, Fibrobacteres, Chlorobi/Bacteroidetes,
Chlamydiae/Verrucomicrobia, Planctomycetcs, Acidobacteria, Chrysiogenetes,
Deferribacteres, Fusobacteria, Gemmatimonadetes, Nitrospirae, Synergistctes, Dictyoglomi,
Lentisphaerae Bacillales, aceae, Listeriaceae, lococcaeeae, Lactobacillales,
Enterocoecaceae, acillaceae, Leuconostocaceae, Streptococcaceae, Clostridiales,
Halanaerobiales, Thermoanaerobacterales, Mycoplasmatales, Entomoplasmatales,
Anaeroplasmatales, Acholeplasmatales, Haloplasmatales, Actinomycineae,
Aetinomycetaceae, bacterineae, Mycobactcriaceae, Nocardiaceae,
PCT/l82012/002950
Coryncbacteriaceac, neae, Frankiaecac, Micrococcineac, Brevibacteriaccae, and
Bifidobacteriaceae.
For pharmaceutical use, a composition of the disclosure should comprise minicells
that are ed as thoroughly as possible from immunogenic components and other toxic
contaminants. Methodology for purifying bacteri ally derived minicells to remove free
endotoxin and parent bacterial cells are described in , which is incorporated
by reference here in its entirety. Briefly, the purification process achieves removal of
(a) smaller vesicles, such as membrane blebs, which are generally smaller than 0.2 pm in
size, (b) free xins released from cell membranes, and (c) parental ia, r live
or dead, and their , which are sources of free endotoxins, too. Such removal can be
implemented with, inter alia, a 0.2 um filter to remove smaller vesicles and cell debris, a
0.45 um filter to remove parental cells following induction of the parental cells to form
filaments, otics to kill live bacterial cells, and antibodies against free xins.
Underlying the purification procedure is a discovery by the t inventors that,
despite the difference of their bacterial sources, all intact minicells are approximately 400 nm
in size, i.e., larger than membrane blebs and other smaller vesicles and yet smaller than
parental bacteria. Size determination for minicells can be accomplished by using solid—state,
such as on microscopy, or by liquid-based techniques, e.g., dynamic light scattering.
The size value yielded by each such que can have an error range, and the values can
differ somewhat between techniques, Thus, the size of minicells in a dried state can be
measured via electron microscopy as imately 400 um i 50 nm. On the other hand,
dynamic light scattering can measure the same minicells to be approximately 500 nm $50 nm
in size. Also, drug-packaged, ligand-targeted minicells can be measured, again using
dynamic light scattering, to be approximately 600 nm i 50 nm.
This scatter of size values is readily accommodated in practice, e.g., for purposes of
isolating minicells from immunogenic components and other toxic contaminants, as
described above. That is, an intact, bacterially d minicell is characterized by cytoplasm
surrounded by a rigid membrane, which gives the minicell a rigid, spherical structure. This
structure is evident in transmission-electron micrographs, in which minicell diameter is
PCT/l82012/002950
measured, across the minieell, between the outer limits of the rigid membrane. This
measurement es the above-mentioned size value of 400 nm :t 50 nm.
Another structural element of a minieell derived from Gram-negative bacteria is the
O-polysaccharidc component of lipopolysaccharide (LPS), which is embedded in the outer
membrane via the lipid A anchor. The component is a chain of repeat carbohydrate-residue
units, with as many as 70 to 100 repeat units of four to five sugars per chain. Because these
chains are not rigid, in a liquid environment, as in vivo, they can adopt a , flexible
structure that gives the l ance of seaweed in a coral sea environment; z‘.e., the
chains move with the liquid while remaining anchored to the minieell membrane.
] Influenced by the O-polysaccharidc component, dynamic light scattering can
provide a value for minieell size of about 500 nm to about 600 nm, as noted above.
Nevertheless, minieells from Gram-negative and Gram-positive bacteria alike readily pass
through a 0.45 um filter, which ntiates an effective minieell size of 400 nm :I: 50 nm.
The above-mentioned scatter in sizes is encompassed by the present ion and, in
particular, is denoted by the er ximately” in the phrase “approximately 400 nm
in size” and the like.
In on to toxic contaminants, a composition of the disclosure can contain less
than about 350 EU free endotoxin. Illustrative in this regard are levels of free cndotoxin of
about 250 EU, about 200 EU, about 150 EU, about 100 EU, about 90 EU, about 80 EU, about
70 EU, about 60 EU, about 50 EU, about 40 EU, about 30 EU, about 20 EU, about 15 EU,
ab0ut 10 EU, about 9 EU, about 8 EU, about 7 EU, about 6 EU, about 5 EU, about 4 EU,
about 3 EU, about 2 EU, about 1 EU, about 0.9 EU, about 0.8 EU, about 07 EU, about 0.6
EU, about 0.5 EU, about 0.4 EU, about 0.3 EU, about 0.2 EU, about 0.] EU, about 0.05 EU,
and about 0.01 EU, respectively.
A composition of the disclosure also can contain at least about 108 minieells, e.g., at
least about 5 x 108. Alternatively, the composition can contain on the order of 109 or 1010
minieells, e.g., 5 x 109, l x 1010 or 5 x 1010 minieells. Amongst any such number of
minicells, moreover, a composition of the disclosure can contain fewer than about 10
contaminating parent bacterial cells, e.g., fewer than about 9, 8, 7, 6, 5, 4, 3, 2, or 1 parent
bacterial cells.
PCT/[32012/002950
(F) Packaging an Anti-neop/asn‘c Agent into Minicel/s
Anti-neoplastic agents, such as proteins and functional nucleic acids, that can be
d by a nucleic acid, can be introduced into minicells by transforming into the parental
bacterial cell a , such as a plasmid, that s the anti-neoplastic agent. When a
minicell is formed from the parental bacterial cell, the minicell retains certain copies of the
plasmid and/or the expression product, the anti-neoplastic agent. More details of packaging
an sion product into a minicell is provided in W0 03/033519, the content of which is
incorporated into the present disclosure in its entirety by reference.
Data presented in W0 03/033519 demonstrated, for example, that recombinant
minicells carrying ian gene expression plasmids can be delivered to phagocytic cells
and to non-phagocytic cells. The application also described the genetic transformation of
minicell—producing parent bacterial strains with heterologous nucleic acids d on
episomally-replicating plasmid DNAs. Upon separation of parent bacteria and minicells,
some of the episomal DNA segregated into the minicells. The resulting recombinant
minicells were readily engulfed by mammalian phagocytic cells and became degraded within
intracellular phagolysosomes. Moreover, some of the inant DNA escaped the
phagolysosomal membrane and was transported to the mammalian cell nucleus, where the
recombinant genes were expressed.
Nucleic acids also can be packaged into minicells directly. Thus, a nucleic acid can
be packaged directly into intact minicells by co-incubating a plurality of intact minicells with
the nucleic acid in a . The buffer composition can be varied, as a on of conditions
well known in this field, in order to optimize the g of the nucleic acid in the intact
minicells. The buffer also may be varied in ence on the nucleotide sequence and the
length of the nucleic acid to be loaded in the minicells. Once packaged, the nucleic acid
s inside the minicell and is protected from degradation. ged incubation studies
with siRNA-paekaged minicells incubated in sterile saline showed, for example, no leakage
of siRNAs.
In other embodiments, multiple nucleic acids directed to different mRNA targets can
be packaged in the same minicell. Such an approach can be used to combat drug resistance
and sis resistance. For example, cancer patients routinely exhibit resistance to
WO 88250 PCT/[82012/002950
chemotherapeutic drugs. Such resistance can be mediated by over—expression of genes such
as multi-drug ance (MDR) pumps and anti-apoptotic genes, among others. To combat
this resistance, minicells can be packaged with therapeutically significant concentrations of
functional c acid to soeiated genes and administered to a patient before
chemotherapy. Furthermore, packaging into the same minicell multiple functional nucleic
acid ed to different mRNA targets can enhance therapeutic success since most
molecular targets are subject to mutations and have multiple alleles. More s of directly
packaging a nucleic acid into a minicell is provided in , the contents of
which are incorporated into the present disclosure in its entirety by reference.
Small molecule drugs, whether hydrophilic or hydrophobic, can be packaged in
minicells by creating a concentration nt of the drug between an extracellular medium
containing minicells and the minicell cytoplasm. When the extracellular medium contains a
higher drug concentration than the minicell cytoplasm, the drug naturally moves down this
concentration gradient, into the minicell cytoplasm. When the concentration gradient is
reversed, however, the drug does not move out of the minicells.
To load minicells with drugs that normally are not water soluble, the drugs initially
can be dissolved in an appropriate solvent. For example, Paclitaxel can be dissolved in a 1:1
blend of ethanol and cremophore EL (polyethoxylated castor oil), followed by a dilution in
PBS to achieve a on of Paclitaxel that is partly diluted in aqueous media and carries
minimal amounts of the organic solvent to ensure that the drug remains in on. Minicells
can be incubated in this final medium for drug loading. Thus, the inventors discovered that
even hydrophobic drugs can diffuse into the cytoplasm or the membrane of minicells to
achieve a high and therapeutically cant cytoplasmic drug load. This is unexpected
because the minicell membrane is composed of a hydrophobic phospholipid bilayer, which
would be ed to prevent diffusion of hydrophobic molecules into the cytoplasm.
Example 10 below demonstrates the leading into minicells of a diversity of
representative small molecule drugs, illustrating ent sizes and chemical properties:
Doxorubicin, Paclitaxel, Fluoro-paclitaxel, Cisplatin, Vinblastine, Monsatrol, ylate
synthase (TS) tor 081-7904, lrinotecan, rouraci], Gemcitabine, and Carboplatin.
Across the board, moreover, the resultant, small molecule drug-packaged minicells show
PCT/IBZOI2/002950
significant anti-tumor efficacy, in vitro and in vivo. These data presented herein, therefore,
clearly demonstrate the iveness and versatility of the miniccll loading s.
(G) Directing Mim'cells to Specific Mammalian Cells
Pursuant to a further aspect of this disclosure, the minicells of a composition, as
described above, are directed to a target mammalian tumor cell via a ligand. In some
embodiments the ligand is “bispecific.’ , That is, the ligand displays a specificity for both
miniccll and mammalian (tumor) cell components, such that it causes a given miniccll to bind
to the target cell, whereby the latter engulfs the former. Use of bispecific ligands to target a
miniccll to a tumor cell is further described in W0 05/056749 and W0 05/079854, the
respective contents of which are orated here in the entirety by reference. Once such a
ligand is ed to a miniccll, the pied specificity (“monspecificity”) of the ligand
pertains until it cts with the target (tumor) mammalian cell.
The ligand can be expressed from within the minicells or their parents and then is
displayed on the minicells surface. Alternatively, the ligand can be attached to (“coated on”)
the cell membrane of the minicells, e.g., by virtue of ligand—receptor interaction. In either
instance the ligand does not require a specificity to the minicell and only displays a
city to a component that is teristic of mammalian cells. That is, such component
need not be unique to tumor cells, per se, or even to the particular kind of tumor cells under
treatment, so [mg as the tumor cells present the component on their cell surface. Upon
intravenous administration, minicells accumulate rapidly in the tumor microenvironment, as
the present inventors discovered (see also the examples below). This accumulation,
occurring as a on of the above-described leaky tumor vasculature, effects ed
delivery of miniccll-packaged therapeutic payload to cells of the tumor. Still, it can be
helpful and at times is preferred, in keeping with the disclosure, for the ligand to target a
component of a tumor to be treated.
In either case minicells contained in an administered composition of the disclosure,
upon accumulation in the brain tumor microenvironment as described above, contact and
bind to the targeted tumor cells, eliciting their uptake into the cells, which then are affected
by the therapeutic d. That payload can be a cytotoxic drug, e.g, doxorubicin or any
PCT/[32012/0029S0
other anti-neoplastic drug, as described above. The payload also can be siRNA or miRNA,
eg., an anti-apoptosis RNAi ce such as anti-Bcl2.
The inventors found that this targeted delivery approach is broadly applicable to a
range of ian tumor cells, including cells that normally are tory to specific
adhesion and endocytosis of minicells. For ce, ligands comprised of an antibody
directed at an anti-HER2 receptor or anti-EGF receptor efficiently bind minicells to the
respective receptors on a range of ed, non-phagocytic cells. These cells include lung,
ovarian, brain, breast, prostate and skin cancer cells.
The binding thus achieved precedes rapid endocytosis ofthe minicells by each type of
the non-phagocytic cells. More generally, a suitable target cell for the present disclosure is
characterized by sion of a cell surface receptor that, upon binding of a ligand,
facilitates endoeytosis. l-lost cells normally are resistant to adhesion. Therefore, when
d by a ligand, the host cell activates its endocytosis mechanism to remove the ligand.
The term “endoeytosis” encompasses (I) phagocytosis and (2) tosis, itself a
category inclusive of (2a) macropinocytosis, which does not require receptor binding, as well
as of (2b) elathrin-mcdiated endoeytosis, (2e) caveolae-mediated endocytosis and (2d)
clathrin- / caveolae-independent endocytosis, all of which tend to access the late-
endosome/lysosome y. The interaction between the ligand on a minicell and a
mammalian cell surface or, the present inventors discovered, activates a particular
tosis pathway, ing receptor mediated endoeytosis (rME) to the late-
endosomal/lysosomal tment. By virtue of such an endocytosis pathway, the present
inventors fithher discovered that the minicells were able to release their payload into the
cytoplasm of the target mammalian cell. In the event the payload is an encoding c acid,
the nucleic acid not only is not completely degraded in the late—endosomal/lysosomal
compartment, but also is expressed in the target mammalian cell.
Ligands useful in the above-described targeted delivery approach, pursuant to this
disclosure, include any agent that binds to a surface component on a target cell and to a
surface component on a minicell. Preferably, the surface component on a target cell is a
receptor. The ligands can se a polypeptide and/or carbohydrate component.
Antibodies are preferred ligands.
PCT/132012/002950
For example, an antibody that carries city for a surface component, such as a
tumor n, on the target mammalian brain tumor cells can be used efficiently to target the
minicells to the target cells in the brain tumor to be treated. Examples of cell surface
ors include epidermal growth factor or (EGFR), vascular endothelial growth
factor receptor ), platelet-derived growth factor receptor (PDGFR) and insulin-like
growth factor or (lGFR), which are all highly expressed in a range of solid tumors,
including brain tumors and folate receptor that is over expressed in some pituitary adenomas.
The bispecific ligand can also be targeted to mutant or variant receptors e.g. the IL-13Ra2
receptor that is expressed in 50% to 80% of human GBMs (Debinski et al., 2000; Jarboe et
al., 2007; Okada et al., 2008; y et al., 2008) but differs from its physiological
counterpart 1L4R/1L13R which is expressed in normal tissues (Hershey 2003). 1L13Ra2 is
virtually absent from normal brain cells (Debinski and Gibo 2000). Additionally, tumors that
metastasize to the brain may over express certain receptors and these receptors can also be
suitable targets. For example, one study showed (Da Silva et al., 2010) that brain ases
of breast cancer expressed all members of the HER family of tyrosine kinase ors.
HER2 was ied and overexpressed in 20% of brain metastases, EGFR was
overexprcssed in 21% of brain metastases, HER3 was overexprcsscd in 60% of brain
ases and HER4 was overcxpressed in 22% of brain metastases. Interestingly, HER3
expression was increased in breast cancer cells residing in the brain.
Preferred ligands comprise antibodies and/or antibody derivatives. In its present use,
the term “antibody” encompasses an immunoglobulin molecule obtained by in vitro or in vivo
generation of an immunogenic response. Accordingly, the ody” category includes
monoclonal antibodies and humanized antibodies, as well as antibody derivatives, such as
single-chain antibody fragments (scFV), bispecific antibodies, etc. A large number of
different bispecific protein and antibody-based ligands are known, as evidenced by the
review article of Caravclla and Lugovskoy (2010), incorporated here by reference in its
entirety. Antibodies and antibody derivatives useful in the present disclosure also can be
obtained by recombinant DNA techniques.
PCT/182012/002950
(H) Formulations and Administration Routes and Schedules
Formulations of a composition of the disclosure can be presented in unit dosage form,
e.g., in ampules or vials, or in multi-dose containers, with or without an added preservative.
The formulation can be a solution, a suspension, or an emulsion in oily or aqueous vehicles,
and can contain forrnulatory agents, such as ding, stabilizing and/or dispersing agents.
A suitable solution is isotonic with the blood of the recipient and is illustrated by saline,
Ringer's solution, and dextrose solution. Alternatively, formulations can be in lized
powder form, for reconstitution with a suitable e, e.g., sterile, pyrogen-free water or
physiological saline. The formulations also can be in the form of a depot preparation. Such
long-acting formulations can be administered by implantation (for instance, subcutaneously
or intramuscularly) or by intramuscular injection.
In some aspect, a minicell-containing composition that includes a therapeutically
effective amount of an anti-neoplastic agent is provided. A “therapeutically effective”
amount of an anti-neoplastic agent is a dosage of the agent in question, e.g., a siRNA or a
chemotherapeutic drug that invokes a pharmacological se when administered to a
subject, in accordance with the present disclosure,
In the context of the present disclosure, therefore, a therapeutically effective amount
can be gauged by reference to the prevention or amelioration of the brain tumor or a symptom
of brain tumor, either in an animal model or in a human subject, when minicells carrying a
therapeutic payload are administered, as r described below. An amount that proves
“therapeutically effective ” in a given instance, for a particular t, may not be
effective for 100% of subjects similarly treated for the brain tumor, even though such dosage
is deemed a “therapeutically ive amount” by skilled practitioners. The appropriate
dosage in this regard also will vary as a function, for example, of the type, stage, and ty
of the brain tumor. In any event, the present rations of in vitro testing les 3 and
4) and in. viva testing (Examples 5, 7 and 8) ing to the present disclosure, as well as of
methodology for quantifying the bution of drug in viva (Example 9), when considered in
light of the entire description, empower a person knowledgeable in pre-clinical and clinical
testing of drug candidates to determine, through routine experimentation, the therapeutically
ive amount of active agent for a particular indication. Likewise, when “therapeutically
effective” is used to refer to the number of minicells in a pharmaceutical composition, the
PCT/[82012/002950
number can be ascertained based on what anti-neoplastic agent is packaged into the minicclls
and the efficacy of that agent in treating a brain tumor. The therapeutic effect, in this regard,
can be measured with a clinical or pathological parameter such as tumor mass. A reduction
or reduced increase of tumor mass, accordingly, can be used to measure therapeutic effects.
Formulations within the disclosure can be administered via various routes and to
various sites in a mammalian body, to e the therapeutic effect(s) desired, either locally
or systemically. In a particular aspect, the route of administration is intravenous injection.
In general, formulations of the disclosure can be used at appropriate dosages defined
by routine testing, to obtain optimal physiological effect, while minimizing any potential
toxicity. The dosage regimen can be ed in ance with a variety of factors
including age, weight, sex, medical condition of the t; the severity or stage of brain
tumor, the route of administration, and the renal and hepatic function of the patient.
Optimal precision in achieving trations of miniccll and eutic agent
within the range that yields maximum efficacy with minimal side effects can and typically
will require a regimen based on the kinetics of agent availability to target sites and target
cells. Distribution, equilibrium, and elimination of minicells or agent can be ered
when determining the optimal concentration for a treatment regimen. The dosage of
minicells and therapeutic agent, respectively, can be ed to achieve desired effects.
Moreover, the dosage stration of the formulations can be optimized using a
phamiacokinetic/phamiacodynamic modeling system. Thus, one or more dosage regimens
can be chosen and a pharmacokinetic/phaimacodynamic model can be used to ine the
pharrnacokinetic/pharmacodynamic profile of one or more dosage regimens. Based on a
particular such profile, one of the dosage ns for administration then can be selected
that achieves the d pharmacokinetic/phannacodynamic response. For example, see
WO 00/67776.
A formulation of the disclosure can be administered at least once a week to a brain
tumor patient, over the course of l weeks. Thus, the formulation can be administered at
least once a week, over a period of several weeks to several months.
More specifically, inventive formulations can be administered at least once a day for
about 2, 3,4, 5, 6, 7, 8, 9, 10, 11, 12, l3, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27,
PCT/182012/002950
28, 29, 30 or 3] days. Alternatively, the formulations can be administered about once every
day or about once every 2, 3, 4, 5, 6, 7, 8, 9,10,11,12, l3,l4,15,16,17,18, 19, 20, 21, 22,
23, 24, 25, 26, 27, 28, 29, 30 or 31 days or more.
In another embodiment of the sure, formulations can be stered about
once every week or about once every 2, 3, 4, 5, 6, 7, 8, 9, 10, ll, 12, l3, I4, 15, 16, 17, 18,
19 or 20 weeks or more. Alternatively, the formulations can be administered at least once a
week for about2, 3, 4, 5, 6, 7, 8, 9, 10, ll, 12, I3, 14, 15, l6, 17, 18, 19 or 20 weeks or more.
Alternatively, the formulations can be administered about once every month or about
once every 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 months or more.
The formulations can be administered in a single daily dose. Alternatively, the total
daily dosage can be administered in divided doses of two, three, or four times daily.
The following examples are illustrative only, rather than limiting, and provide a more
complete understanding of the disclosure.
Example 1. Preparation ofdoxorubicin-packaged, canine EGFR-targeted lls
Minicells were derived from a minCDE- chromosomal deletion mutant of Salmonella
enterica serovar Typhimurium, S. typhimurimn, purified, packaged with doxorubicin (dox)
and targeted via attachment of a bispecific monoclonal antibody (MAb) comprising anti-
minicell surface O-polysaccharide and anti-canine EGFR specificities, (designated,
EGFRminicellsDox), as previously described by rmid et al. (2007).
The EGmminicellsmx were initially terized for their suitability for i.v.
administration into seven dogs with late-stage brain cancers (dogs designated BCD-l to
. Two additional dogs, BCD-8 and BCD-9 presented at the Veterinary Specialist
Centre but did not go into the study due to the very late stage of their brain tumors and were
euthanized. Brain biopsy samples provided the respective brain tumor cells for z‘n—vitro
studies.
Example 2. Characterisation ofanti-human EGFR onal antibody
for g to canine brain tumor cells
Upregulation and overexpression of EGFR is well known in ~60% ofGBM cases in
both humans (Smith et (1]., 200]) and dogs ns et al., 2010). Given the unavailability of
PCT/IBZOIZ/002950
a specific canine EGFR MAb, the commercially available anti-human EGFR MAb was tested
in canine and human brain tumor cell lines to determine cross-reactivity of the MAb to EGFR
on canine brain tumor cells.
Where feasible, brain tumor biopsy samples were obtained from case study dogs.
Tissue samples from BCD-l, -8 and -9 were treated for 10 min with 1mg/ml collagenase in
Dulbecco’s modified Eagle’s medium (DMEM) media containing 10% fetal calf serum
(FCS) and Penstrep. Undigested tissue was removed by filtration through a double layer of
sterile gauze swab. Collagenase digestion was d by diluting the cells with 5 ml media
and centrifuging at 1,200g for 5 min. Cells were washed with an onal 5 ml media
followed by repeat centrifugation and resuspension. Cells were then plated in tissue culture
flasks.
{0157] The dog GBM cell line, .13"? (Rainov et a/., 2000), was obtained from Dr. Michael
Berens of the Translation cs Research Institute ix, AZ, USA). All canine brain
tumor cell cultures were maintained in DMEM supplemented with 10% (vol/vol) FCS,
100 U/ml penicillin, 100 U/ml streptomycin, 2 mM l-glutamine, and 2 mM ential
amino acids.
Human GBM-astrocytoma epithelial cell line (U87-MG) was ed from the
American Type Culture Collection (ATCC) and was grown in OPTl-MEM media
(Invitrogen, USA) with 5% fetal bovine serum (PBS).
Cells were collected by detaching from the flask with 2mM EDTA/PBS and divided
into 1 x 106 cells/tube. Cells were washed twice in blocking solution (PBS with 2% BSA and
0.1% sodium azidc), and incubated in blocking solution for 10 min on ice, followed by
incubation with l rig/pl anti-human EGFR monoclonal antibody (lgGZa; chem) for 45
min on ice. After two washes with blocking solution, cells were incubated with R-
phycoerythrin conjugated goat anti-mouse IgG (Molecular /Invitrogen) for 45 min on
ice and with gentle agitation. After two washes in blocking solution, cells were resuspended
in PBS and used for flow cytometry analysis. As controls, PBS d of the primary
antibody was used to determine autofluorescence.
Stained cell suspensions were ed with the flow cytometer PC 500 using CXP
Cytometer sofiware (Beckman C0ulter). The number of EGF receptors was determined by
PCT/[32012/002950
analytical flow eytometry in comparison with fluorescent ocrythrin microbcad
standards um R-PE MESF beads; Bang Laboratories Inc, Fishers, IN, USA). The
calibration curve was generated by plotting the given number of equivalent R-phycoerythrin
molecules per bead versus the log of its mean cence intensity. Cellular fluorescence
intensity was olated onto a standard fluorescence calibration curve. The values of mean
fluorescence were converted into number of antibodies bound per cell after subtraction from
the negative control.
] The results showed (Fig. 1) that the MAb strongly binds to EGFR on both canine
(J3T, BCD-l, -8 and -9) and human (U87-MG) brain cancer cells.
Receptor quantitation studies using FACS analyses showed (Fig. 1) EGFR
concentration per cell (in a decreasing order) for BCD-l, U87-MG, BCD-9, BCD-8 and JBT
cells was 2,866,854, 1,465,755, 930,440, 774,352 and 2 respectively. This suggested
that each of the cell types over-express EGFR.
The binding cross~reactivity of the anti-human EGFR MAb to canine EGFR was
therefore confirmed following the in vitro binding assay to canine and human brain cancer
cells.
Therefore, to e active targeting of brain tumor cells. anti-human EGFR MAb
was selected to coat the Dex-packaged minieells.
Example 3. Determination ofsensitivity ofcanine brain cancer cells
to chemotherapeutic drug doxorubicin
Prior to using dox-packaged, EGFR-targeted minicells to treat the dogs with late-stage
brain cancers, it was important to determine ifthe canine brain tumor cells were ive or
resistant to the chemotherapeutic drug doxorubicin.
Canine brain tumor cells BCD-l , -8, -9 and 137" and human brain tumor cell line U87-
MG were seeded into 96 well plates at 5 x 103 cells per well. Cells were incubated overnight
at 37°C, 5% C02.
Doxorubicin was added to cells in IOOnL of relevant media containing serum at
concentrations ranging from 1.7nM to 8,600nM and incubated for 72 hours.
PCT/182012l002950
To measure the cytotoxic effect of bicin an MTS cell proliferation assay was
performed To each well 20uL of MTS solution (CellTitre 96® Aqueous One MTS reagent —
Promega) was added and incubated in the dark for 30 minutes. Absorbance was read at a
wavelength of 490nm. Data was analysed in Prism GraphPad (La Jolla, CA, USA) using non-
linear regression and a 4—parameter curve fit.
The cell proliferation assay showed that all the above cell lines were equally sensitive
to doxorubicin (Fig. 2).
Example 4. Efficiency ofbinding ofEGF“minicellsom to canine brain tumor cells
The canine and human tumor cells were transfected for 2 hrs with specifically— and
non—specifieally-targeted minicells, hGFRminicells.)0x and gplz0minicellsDO,‘ respectively, and
post-washing off non-adherent minicells, the cells were treated with anti-mouse lgGZa MAb
tagged with Alcxa-Fluor 488 cent dye (AF-488). The gp120 MAb is directed to the
human immunodeficiency virus 1 envelope glycoprotein gp120 and is not found on the
e of any of the brain tumor cell lines tested in this study. The cells were then ed
using FACS. The results showed (Fig. 3) that in each case, > 95% of the cells strongly
ced when treated with EGFRminicellsDox and
the cells showed no fluorescence when
treated with the control gplZOminicellspox.
The observed binding efficiency was further confirmed using cence
microscopy to directly visualize the binding 0f EGFRminicellsD0x to brain tumor cells and also
the delivery of doxorubicin intracellularly in the cancer cells.
The EGI‘RminicellsDox were used to transfect the canine brain tumor and human control
cell lines. Three hours post-transfcction and washing off excess unbound minicells, thc
lls still adherent to the cell lines were revealed by labelling the EGFR targeting MAb
with anti-IgG2a-AF488. The results showed (Fig. 4) that the specifically targeted minicells
inicellsDOX) bound in large numbers to the human and canine brain cancer cells while
the control lls did not. Additionally, most of the cells treated with EGFRminicellsDox
showed dox autofluorescence in the cell nucleus suggesting that a cant number of
minicells had been endocytosed, lysed in intracellular lysosomes and the dox had been
released intracelluarly. This mechanism of intracellular delivery of drugs via bispeeific
PCT/[32012/002950
antibody-targeted, drug—packaged minicells to different tumor cell lines has been delineated
before by the authors of the present application and published (MacDiarmid et al., 2007).
The above results provided the rationale for packaging the minicells with dox and
targeting them to EGFR.
Example 5. Treatment n late-stage brain cancer dogs
EGFR
with minicellspm. and anti-tumor efficacy
Dogs in this study were pet dogs presenting as patients to the nary Specialist
Centre (VSC) or the Small Animal Specialist Hospital (SASH), in Sydney, Australia. Study
participation was offered to patients where rd therapy had been declined by the dog's
owner, or in cases of advanced e in which no meaningful standard therapy existed.
Dogs were treated in compliance with National Health and Medical Research l,
Australia ines for the care and use of laboratory animals, and with EnGeneIC Animal
Ethics Committee approval. Signed informed consent was obtained from all owners. All
patients underwent necropsy examination at the time or death due to any cause.
All brain tumors were diagnosed by histology or cytology where feasible.
Antemortem ses were based on a combination of characteristic appearance on
magnetic resonance g (MRI) and clinical signs. Histological diagnosis was deemed
too ve in these brain tumor cases and diagnosis was confirmed by necropsy.
Staging methods used varied depending on the histologic type and anatomic site of
the tumor, and the clinical . These included, but were not limited to, physical
examination, complete blood count, serum biochemistry profile, urinalysis, coagulation
profile, thoracic radiographs, abdominal ultrasound and magnetic resonance imaging (MRI).
MRI scans were med with a 1.5T Phillips a.
Dogs were eligible for the study provided they had adequate performance status, and
hematologic and serum biochemical parameters to undergo therapy. All dogs had measurable
disease at study entry but there were no restrictions on stage of disease or disease burden.
Patients were permitted to continue with medications to aid in the prevention of seizures and
CNS edema. Medications which had been previously prescribed for concomitant conditions
were also allowed to be ued. Alternative therapies were not permitted during the trial
period.
PCT/[32012/002950
Treatment with l x 10'0 EGFRminiccllsDox per dose was performed on a weekly basis.
Treatment was administered via an aseptically placed peripheral vein catheter (left cephalic)
in 2 ml over a 2 minute infusion.
Patients were ed to hospital and 3 ml blood was collected via jugular
venipuncture. This was placed into potassium EDTA for haematology and serum clot
activator tubes for biochemistry. An additional 5 ml was collected pre-administration of
EGFRminicellsn0X and at 4 hrs post-minicell administration. Dogs were monitored throughout
the clinical treatment period and in the absence of any toxic side effects by 4 hrs post-
E(’FRminicellsDo,‘ treatment, the dogs were sent home.
The blood was placed in a sterile tube, centrifuged at 1,580 x g for 15 min at room
temperature (20 to 22C) and the serum was collected aseptically. Sera were stored at -80°C
until required for cytokine or dy response profiling. Patients were pre-medicated with
chlorpheniramine maleate at 0.5 mg/kg and dexamethasone sodium phosphate at 0.2 mg/kg
minutes prior to ent.
] Case studies were carried out in seven late-stage brain cancer dogs who underwent
initial clinical g with al ations and MRI of the brain.
The canine patients designated BCD-l to BCD-7 showed l clinical signs of late-
stage brain tumors including seizures, ataxia, partial limb paralysis, part loss of peripheral
vision and aggressive behavior (see Table 2, infra).
enous (iv) bolus injections of 1 x 10'0 eellsD0x (2ml) were
stered in the dogs once per week and clinical evaluation, serum hematology,
biochemistry, immune response (antibody titers to minicell dominant antigen, LPS) and
cytokine response studies were carried out each week. MRI scans of the brain were carried
out approximately every 8 weeks to determine anti-tumor response. The dose of minicclls to
administered in the dogs was previously determined from studies in 20 dogs with late-stage
hemangiosarcoma and logy trials in rhesus monkeys (data not shown).
Results showed that the abnormal clinical symptoms of the brain tumor determined at
the time of clinical staging (Table 2) returned to normal after approximately five to fifteen
f FGFR doses 0 minieellsDox.
PCT/[B201 50
Response was assessed by MR] scans. Response was fied according to se
Criteria In Solid Tumors (RECIST v 1.1) for solid tumors. Additionally, brain tumor volume
was assessed using the formula: length x width x height x (it/6). A complete response (CR)
was defined as disappearance of all known gross disease, a partial response (PR) was defined
as a 2 50% decrease in tumor size from ne but not a CR, stable disease was designated
for tumors not meeting the criteria or CR, PR or progressive disease and progressive disease
(PD) was defined as Z 25% increase in tumor size or the ance of new lesions.
The MRI scans showed that in all dogs, the tumor growth had been arrested and in
one case, BCD-2, there was no evidence of the large tumor mass (Fig. 5) after just five doses
of EGFRminicellsDox.
Example 6. Absence oftoxicity in dogs with brain cancer
EGFR
deSpite repeat dosing with minicellsnm
Toxicity was assessed by client questionaire for signs of dysfunction of the
intestinal tract (anorexia, diarrhoea, vomiting, and enteritis) and constitutional signs
(lethargy/fatigue). Haematological and biochemical toxicity was determined on a weekly
basis prior to each treatment. Toxicity was graded according the Veterinary Co-operative
Oncology Group common terminology criteria for adverse events (VCOG-CTCAE)
following chemotherapy or biological anti-neoplastic therapy in dogs and cats v1.0.
Body weight remained unchanged throughout the course of treatment. Body
temperature sed from 385°C to 39°C within the first hour post-dosing and returned to
normal by 4 hours.
Serum from dogs was collected (5 ml) at pre-dosc with EGFRminicellsp0X and 4 h post-
dose. tion of serum biochemical and haematological profiles (Figs. 6 and 7) was
carried out by IDEXX Laboratories (Sydney, Australia). Reference ranges for canines were
provided by IDEXX laboratories.
Serum mistry parameters remained within the normal reference range (Fig. 6).
At the time of initial clinical staging, all dogs showed marked elevation in liver enzymes
alanine aminotransferase (ALT) and ne phosphatase (ALP), likely because all dogs
received tional treatment with glucocorticoid (prednisolone) at doses ranging from 0.5
to 2 mg/kg once a day and phenobarbitone (1mg twice a day) for difficult-to-control seizures.
PCT/IBZOl2/002950
Liver ultrasound was routinely performed for all dogs and did not show any signs of liver
tumors. Throughout the study, the livers ed normal, indicating no adverse events in the
liver despite the repeat doses of EOFRminieellsDox.
The ological indiccs for all dogs also remained within the normal range
throughout the study (Fig. 7).
Example 7. Cytokine and antibody responses in brain cancer dogs
following repeat dosing with EGFRminicellsoax
Canine serum was analysed for canine inflammatory nes TNFa, lL-6 and anti-
atory cytokine IL-lO using ELISA duoset kits supplied by R&D Systems (USA)
following validation of each ELISA according to the manufacturer’s instructions. High
binding ell plates er) were developed using TMB substrate (Sigma) and read in
a Biotek uQuant plate reader at 450 nm.
Inflammatory cytokine, TNFa, responses varied with each dog and showed no
consistent pattem. Three dogs (BCD-Z, -4 and -6) showed no elevation in TNFO. despite
repeat dosing (Fig. 8). BCD-S and BCD-7 also showed no elevation in TNFu till dose 9 and
respectively while the subsequent 3 and 7 doses tively showed a significant rise but
with no clinical adverse signs. BCD-l had elevated TNF a at the time of clinical staging and
the subsequent 97 doses 0f nicellsnm showed no further elevation in TN Fa.
Inflammatory cytokine lL-6 showed a trend where at 4 hr post-dose (Fig. 8), there
was a small spike in IL-6 which returned to normal by 24 hrs. Subsequent doses did not result
in an augmentation of the lL-6 spike and the trend remained the same post-each dose. An
exception was BCD-4 whose IL-6 remained normal throughout the study (39 doses over 288
days).
Interestingly, the anti-inflammatory cytokine lL-lO was elevated when there were
spikes in TNFu and IL-6 (Fig. 8). It is well established that monocytes and macrophages
e lL-10 after activation with various mediators such as bacterial LPS (Sabat er al.,
2010).
LPS purified from S. typhimurium (Sigma) was plated in the wells (250ng/well) in
coating buffer (lOmM Na Carbonate pH 9.6) and incubated overnight at 4”C. Plates were
W0 20131088250
blocked with blocking buffer containing 1% BSA in PBS for 1 h at 37°C. Serial dilutions of
serum samples were added to each plate and incubated at 4"C overnight. After washing,
bound antibodies were detected with goat anti-canine lgG horseradish peroxidase (HRP)
conjugate (RDl).
The antibody titer was defined as the reciprocal serum dilution that gives a half-
maximal Optical Density (450nm) reading. KC Junior Software was used to fit a 2 ter
curve to each serum sample. All samples were analyzed in duplicate and data represent the
standard errors of the mean.
The O-polysaceharide serum antibody titers (Fig. 9) showed a typical response
showing a 20-fold increase in lgG titer by dose thrcc (over three weeks) and d a
u with no further elevation throughout the course of the study for each dog. This is not
surprising since O-polysaeeharidc ent of the LPS is known to be a T-cell independent
type 1 antigen and that these antigens te B cells primarily by ating mitogenie
receptors, for e ike receptors (TLRs).
e 8. Number ofrepeat doses ’]?minicellsoux administered and survival
ofdogs with late-stage brain cancers
Interestingly, dogs BCD-l to BCD-7 survived 822, 709, 471, 288, 408, 140 and 10]
days respectively and received 97, 43, 44, 39, 32, 20 and 13 doses of EGFRminicellsp0x
respectively (Fig. 10). BCD-2, -3 and -5 are on-going and BCD-2 has not received a dose for
over 300 days with no recurrence of the tumor. BCD-4 survived 288 days and remained with
stable disease but succumbed to a kidney infection. Post mortem analysis revealed that the
death was not related to the brain tumor. Surprisingly, despite the very large number of doses
of EGFRminicellsD0x administered systemically, there were no clinical signs of adverse events.
Example 9. ln-vivo imaging ofEGFRminicells in the brain oftwo dogs
with late~stage brain cancer
Nanoparticle biodistribution in vivo, particularly in a large animal species, has been
hampered due to the very small size of the particles, ability to carry sufficient fluorescent
molecules per particle to enable visualization and concentration ed in vivo in any
particular organ. Additionally, the current understanding that nanoparticles larger than 12 nm
would not enter brain tumors due to the presence of the BBB. However, the striking anti-
PCT/[32012/002950
EGFR tumor efficacy observed in all 7 dogs prompted us to determine if the minicellsD0x do
somehow gain entry into brain tumors despite their dingly large size of ~ 400 mm.
The EGFRminteens were radio-labeled with mlodine and 1 x 1010 ls were
administered iv. in BCD-3 and BCD—S. The dogs were sedated and imaged using Single-
photon emission computed tomography (SPECT). Both dogs also had prior MRI scans to
clearly show the tumor size and location.
The animals were injected with approximately 40 MBq of the radiolabelled [ml]-
EGFRminicells and imaged at varying time points over the following 4 h. All imaging was
performed on a Picker 3000XP tn’ple-detector SPECT (Single Photon Emission Computed
Tomography) gamma camera fitted with low energy, all purpose parallel hole collimators. All
acquisitions used a photopeak window setting of 159 keV i 10%. The animals were given
some light anaesthesia prior to imaging. One dog (BCD-3) was imaged non-tomographically
at 30 minutes and 3 hours post-injection in a supine position to study the biodistribution.
le planar images covering head and torso were collected in 256x256 matrices for 2
minutes per bed position at both time points and joined post-acquisition to give whole body
2D scans. All tomographic (SPECT) images were acquired in 128x128 matrices, using 120
projections of 3° radial increments (360° total) for 20 seconds per projection. All data were
erred to an off-line r medicine workstation (HERMES, Nuclear stic,
Stockholm, Sweden) and reconstructed using an iterative reconstruction algorithm (OSEM, 8
subsets, 4 ions). The images were reconstructed with a software zoom of 2.0 to give
voxels measuring l.78><l.78><2.56 mm (XxYxZ). The images were post-reconstruction
filtered with a Butterworth filter of order 10 and cut-off of 1.25 eyelespixel-l. usly
acquired MRI scans on the dogs were imported into the workstation and the ical
(MRI) and functional (SPECT) scans were registered in sofiware.
Whole body scans (Fig. llei and ii) showed intense uptake of the labelled [123]]-
FGFRminicells in the liver from the earliest oint (30 minutes post-injection). This fact,
plus lack of early visualization of thyroid, indicated good labeling of the minicells. Excretion
into bowel was visible in the later , as was some bilateral glandular uptake in the neck
and a small amount of thyroidal uptake of (presumed) free [mm-iodide present.
2012/002950
The SPECT images of the brain (Figs. 1 lai-iii and 1 lbiii; SPECT) showed a focus of
radioactivity in the area corresponding to the brain tumor seen on the MRI scan (Figs. llai-iii
and 1 lbi; MRI). The co-registered T1 post-contrast MR1 and SPECT id images (Figs.
llai-iii and llbii; MRI) showed that the focused radioactivity was localized in the
core of the tumor in each dog.
These examples demonstrate anti-tumor efficacy in 100% of the cases with late—stage
brain tumors, an edented result achieved with the present disclosure. It also is a very
surprising , given the following considerations.
1. Drugs sized on the order of doxorubicin (579.98 Daltons), such as paclitaxel (853.9
Daltons) and vinblastine (810.9 Daltons), would never have been considered heretofore
for systemic (iv) delivery and treatment of brain tumors. Given the consensus cutoff of
abut 400 Daltons, as discussed above, they were not expected to cross the BBB at all.
Decades of research have d lomide as the sole FDA-approved drug for the
treatment of brain cancers; this, because it is the only drug that has a molecular weight,
194.15 Daltons, that is below the perceived 400-dalton cutoff for crossing the BBB.
Even if it had been considered for treatment of brain tumors, doxorubicin in
conventional chemotherapy normally is administered at a dose of 100 mg to 125 mg in
an average patient (60 kg). This equates to 100,000 ug to 125,000 ug per i.v. dose,
deemed a minimum to achieve therapeutic efficacy in treating some cancers. Pursuant
[0 EGFR ~- .
to the disclosure, by contrast, the doxorubicin dose carried in 1 x 1 0 mlnlCCiiSDoxlS
about 4 ug, which is 25,000-fold to 31,250-fold less than the dose stered for
conventional dox herapy. This divergence from conventional practice, in
accordance with the disclosure, would have combined with the current understanding of
cancer treatment to dissuade the clinician from considering the ct of such a low
drug dose in any context, let alone in the context of brain cancers.
The use of the minicell delivery vehicle pursuant to the disclosure contradicts the
sus size limits, discussed above, which in turn are informed by a conventional
view of the breached BBB in brain tumors. Yet, the data obtained with the disclosure
show that intact, bacterially derived minicells rapidly enter into brain tumors in
significant concentrations, enabling, for e, the imaging of the radiolabeled
minicells in the brain tumor microenvironment. The results also demonstrate highly
PCT/1820121002950
significant tumor stabilization/regression in every one of the subjects treated, an
edented achievement that underscores an ive therapeutic paradigm, in
keeping with the disclosure, for a field of clinical oncology previously typified by only
abysmal results.
WO 88250 PCT/182012/002950
a3on$80528 380m Barnabas EmcmzaE nEommchE 38:58.“th «EB
289.0 :03 25%.
mzocov Eu Em:
2 £8
SE we
6:0 E
”Ema: 9:0: .aoEmfl cozmimeo cEE mama
.93 bazaaa
“HE Emt 60:80ng gown—V
.8 :83:
3:80 9.: Em:
E ._mmma.:§? .omfimmk 2: 2.8% .mp5:
EwommoBSoZ E 2:
£2 88:. £0323
E“ gfioommo mas—wow E .358: Emt
.« €339 4222 285E onE 312235 .595 SB 02382505
2&3 .25 wwfinsc 338%?
REE—U WEE ,2me aE 0.63m Em: .mESNBm .mctzfiom Emu .mctznmom SEE £0.
.anctonSE .85 v.33 ioa
.56 oéaoootgoa bE—Ema 8m 8m 25¢ 8m =< 2:
co— 9 o. .22
mo 22 .%2
oEH 895% =£ 3:885 c2865 3:885 .moxocoh @25on c2585 mazes E. :o 6: Eon:— £3 2E 63
E!225m 0:: Egan 232 0.32
m: m; m; mi
m n wEEoE N. _
3325 éeumgu
-8353 ho>ot~om 5290 8550M Err—oh
£80 BEBE 305320 .5th BEmEotSm ::m Egg 8:
min:
3:5 83%; a; N mo; Nvd owd 32::
EN 56mm med ocdm ow.mm ESQ
.N we: M00.
03¢ 595 32:3 sea 25m Ndom .méUm wA—Um héom ”32
2012/002950
Example 10. Packaging ofa y ofsmall molecule drugs into lls
This example illustrates both the feasibility of loading a diverse number of small
molecule drugs into minicells and the cant anti-tumor efficacy of the resultant, small
molecule drug-packaged minicell-containing compositions. The involved small molecule
drugs were:
FQWWPCW> Doxorubicin,
Paclitaxel,
Fluoro-paclitaxel,
Cisplatin,
stinc,
Monsatrol,
Thymidylate synthase (TS) inhibitor 081-7904
Irinotecan,
:— S-Fluorouracil,
h. Gemcitabine, and
K. CarbOplatin.
Packaging of Doxorubiein, vinblastine and paclitaxel. The effectiveness of
packaging of doxorubicin, fluorescent stine and flouro-paclitaxel into intact minicells
has been demonstrated in the present inventors’ publication, MacDiarmid et a/., Cancer Cell
11: 431-45 (2007). Figure 1E of MacDiarmid et al. Cancer Cell (2007), with different
fluorescence colors to show that minicells were packaged with large s of doxorubicin
(DOX), vinblastinc (VIN) and axcl (PAC), respectively.
Doxorubicin, flouro-paclitaxel and cisplatin did not leak out of minicells once
packaged. MacDiarmid et al. Cancer Cell (2007) further employed kinetics to demonstrate
that, not only were drugs (doxorubicin, flouro-paclitaxel and tin) sufficiently loaded
into intact minicells, these drugs drugs did not leak out of the intact minicells once packaged
(see, Figure 2A in the article).
Doxorubicin and paclitaxel packaged minicells were effective in treating breast
cancer xenografts. Moreover, data presented in Figure 4A of MacDiannid et al. Cancer
PCT/[32012/002950
Cell (2007) show that human breast cancer xenografts were effectively treated with
bicin- or paclitaxel-packaged minicells.
umor effect of monastrol-packaged minicells. Another article published by
the present ors, MacDiarmid er al., Cell Cycle 17: 1-7 (2007), presented data to
trate the effectiveness of monastrol-packaged minicells in inhibiting tumor growth in
mice containing human breast cancer xenografis (see Figure 1A in the article).
As shown in Fig. 1A, monastrol was ively packaged into intact minicells and
human breast cancer xenograft were effectively treated with monastrol-packaged minicells.
Anti-tumor effect of minicells packaged with thymidilate synthase inhibitor OS]-
7904. Human colon cancer xenografts, likewise, were effectively treated with oaded
minicells. Figure 1B of MacDiarmid et al. (2007) shows that OSIloaded minicells
were more effective, at a dose that was ~385-fold less than the liposomal formulation of OSI-
7904L, than the liposomal formulation OSl-7904L. The minicell delivery vector thus
dramatically increased OSI-7904’s therapeutic index..
Effective treatment of irinotecan-resistant human colon cancer xenografts.
Irinoteean has also been packaged into intact minicells. Further, effective treatment of
irinoteean-resistant human colon cancer xenografts ing dual sequential treatment with
MDRl-packaged minicells followed by irinotecan-targeted minicells are
demonstrated in Figures 5A and 5A in MacDiarmid et al., Nature Biotechnology 27: 643—5]
(2009), another publication by the present inventors.
ive treatment of 5-Fluor0uracil-resistant human colon cancer xenografts.
Like irinotecan, S-Fluorouracil was also packaged into intact minicells and ive
treatment of S-Fluorouracil-resistant human colon cancer afts was achieved following
dual sequential treatment with shRNA-MDRl-packaged minicells followed by 5-
Fluorouracil-targeted minicells. See Supplemental Figures 4A and 4B of MacDiarmid et al.,
(2009).
Effective treatment of human atic cancer xenografts with Gemcitabine
(Gemzar®)—packaged minicells. Fig. 12 demonstrates that human pancreatic cancer
xenografts were ively treated with Gemcitabine (Gemzar®)—packaged minicells.
PCT/182012/002950
Human pancreatic cancer (MIA PaCa) xcnografts in Balb/c nu/nu mice were
administered i.v. with either free Gemzar or EGFR-targeted, -packaged minicells
(EGFRMinicellsGemm). Fig. 12 shows that although the minicell doses carried only ~50 ng of
Gemzar, the anti-tumor y of EGFRMinicellsGemm treatments were just as effective in
terms of anti-tumor cy as free Gemzar that was given at a dose of 400,000 ng per dose.
Carboplatin in treating human breast cancer afts. The effect of
carboplatin-packaged minicells to treat human breast cancer xenografts are demonstrated in
Fig. 13.
Human breast cancer (MDA-MB-468) xenografts in Balb/c nu/nu miccwerc
administered iv. with either free carboplatin or non-targeted minicells ed with
carboplatin or EGFR-targeted, carboplatin-packaged minicells (EGFRMinicellscmopmun). The
results in Fig. 13 show that EGFRMinieellscmoplmin
treatments were highly effective in
achieving tumor stabilization, even though the dose of carboplatin was ~ 1,000-fold lower
than the free carboplatin dose.
’1!U!
PCT/[82012/002950
CITED PUBLICATIONS
, E., Passirani, C., Benoit, JP. Convection-enhanced delivery of nanoparticles for the
treatment for brain . Biomateria/s 30, 2302-23 1 8 (2009).
Behin, A, Hoang-Xuan, K., Carpentier, A.F., Delattre, J.Y. Primary brain tumours in adults.
Lancet 361, 323-331 (2003).
Bickel, U. How to Measure Drug Transport across the Blood-Brain Barrier. NeuroRx. 2, 15—
26 (2005).
Black, K.L., Ningaraj, N.S. Modulation of brain tumor capillaries for enhanced drug delivery
ively to brain tumor. Cancer Control 11, l65-73 (2004).
Bobo, R.I-l., Laske, D.W., Akbasak, A., on, P.F., Dedrick, R.L., Oldfield, EH.
Convection-enhanced ry of macromolecules in the brain. Proc. Natl. Acad. Sci. U S A
91, 2076—2080 (1994).
Borst, P. et al. A family of drug transporters: the multidrug resistance-associated proteins. J.
Natl. Cancer Inst. 92, 1295-1302 (2000).
Caravella .l., Lugovskoy, A. Design of next-generation n therapeutics. Curr. Opin.
Chem. Biol. 14. 520-528 «2010).
Britton, R.A., Lin, D.C., Grossman, A.D. Characterization of a prokaryotic SMC protein
involved in some partitioning. Genes Dev. 12, 1254-9 (1998).
Caplen, NJ. RNAi as a gene therapy approach. Expert Opz'n. Biol. Then 3, 575-86 (2003).
, N.J., Mousses, S. Short interfering RNA (siRNA)-mediated RNA interference
(RNAi) in human cells. Ann. NYAcad. Sci. 1002, 56-62 .
Cecchelli, R., Berezowski, V., Lundquist, S., Culot, M., Renftel, M., Dehouck, M.P., Fenart,
L. ing of the blood-brain barrier in drug discovery and development. Nat. Rev. Drug
Discov. 6, 650-661 (2007).
Chu, C.Y., Rana, T.M. Translation repression in human cells by microRNA-induced gene
silencing requires RCK/p54. PLoS Biol. 4, e210 (2006).
W0 20131088250 PCT/[82012/002950
Clark-Curtiss, J.E., Curtiss, R. 111 Analysis of recombinant DNA using Escherichia coli
minicells. Methods Enzymol. 101, 347-62 (1983).
Da Silva L et al. HER3 and downstream pathways are involved in colonization of brain
metastases from breast cancer. Breast Cancer Res. 12, R46 (1-13) (2010).
Debinski, W., Gibo, BM. (2000) Molecular expression analysis of restrictive receptor for
interleukin 13, a brain associated cancer/testis antigen. Mol. Med. 6, 440—449 (2000).
Debinski, W., Slagle, B., Gibo, D.M., Powers, S.K., Gillespie, G.Y. Expression of a
restrictive receptor for interleukin 13 is associated with glial ormation. J. Neurooncol.
48, 103- 111 (2000).
de Boer, P.A., Crossley, R.E., Rothfield, L.l. Roles of MinC and MinD in the site-specific
scptation block mediated by the MinCDE system of Escherichia coli. J. Bacteriol. 174, 63-70
Dehouek, B., Dehouek, M.P., Fruchart, J.C., Cccchelli, R. Upregulation of the nsity
lipoprotein receptor at the blood-brain barrier: intercommunications between brain capillary
endothelial cells and ytes..1. Cell Biol. 126, 465-473 (1994).
Duan, 2., et al. Inhibition of ABCB] (MDRI) and ABCB4 (MDR3) expression by small
interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells. Mol.
Cancer Ther. 3, 833-8 (2004).
Duxbury, M.S., et al. Systemic siRNA-mediated gene ing : A new ch to targeted
therapy of cancer. Ann. Surg. 240, 667-74 (2004).
Eichler, A.F., Loeffler, J.S. isciplinary management of brain metastases. Oncologist
12, 884—98 (2007).
Fox, B.D., Cheung, V.J., Patel, A.J., Suki, D., Rao, G. Epidemiology of metastatic brain
tumors. m’g. Clin, N. Am. 22, 1—6 (201 l).
Fukuda, M. Radiolabeling oligosaccharides after mild periodate oxidation, Curr. Protocols
Molec. Biol. (Suppl. 26), 17.51—17.58 (1994).
y, R.]., Chendrimada, T.P., Shiekhattar, R. MicroRNA biogenesis: isolation and
characterization of the microprocessor complex. Methods Mol. Biol. 342, 33-47 (2006).
PCT/182012/002950
Groothuis, D.R. The blood-brain and blood tumor barriers: a review of strategies for
increasing drug delivery. Neuro-oncol. 2, 45-59 .
Hadjipanayis, C.G., s-Mayle, W., Deluca, N.A. Therapeutic efficacy of a herpes
simplex virus in combination with radiation or tcmozolomidc for ranial glioblastoma
after convection enhanced delivery. Mal. Ther. 16, 1783—1788 (2008).
Hadjipanayis, C.G., Machaidze, R., Kaluzova, M., Wang, L., Schuette, A.J., Chen, H., er al.
EGFvall antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-
guided convection-enhanced delivery and ed therapy of glioblastoma. Cancer Res. 70,
6303-6312 (2010).
Hassenbusch, SJ, Gunes, S., Wachsman, S., Willis, K.D. Intrathecal clonidine in the
treatment of intractable pain: a phase l/lI study. Pain Med. 3, 85-91 (2002).
Hau, V.S., Huber, J.D., Campos, C.R., Lipkowski, A.W., Misicka, A., Davis, T.P. Effect of
guanidino modification and proline substitution on the in vitro stability and blood-brain
barrier permeability ofendomorphin II. J. Pharm. Sci. 91, 2140-9 (2002).
s, B.T., Davis, T.P. The blood—brain barrier/neurovascular unit in health and disease,
Pharmacological Reviews 57, 173-185 (2005).
Hershey, GK. lL-l3 receptors and signaling pathways: An evolving web. J. Allergy Clin.
Immunol. 111, 677 690 (2003).
Higgins, R]. et al. Spontaneous canine gliomas: overexpression of EGFR, PDGFR alpha and
lGFBP2 demonstrated by tissue rray immunophenotyping. J. oncol. 98, 49-55
(2010).
Hiraga, S., Niki, H., Ogura, T., lchinose, C., Mori, H., Ezaki, 8., Jaffe, A. Chromosome
partitiOning in Escherichia coli: novel s producing anucleate cells. J. ial. 171,
1496-1505 (1989).
Hu, 2., haus, J. Topological regulation of cell division in Escherichia coli involves
rapid pole to pole oscillation of the division inhibitor MinC under the control of MinD and
MinE. M01. Microbiol. 34, 82-90 (1999).
WO 88250 PCT/132012/002950
lreton, K., Gunther, NW. 4th., Grossman, AD. spoOJ is required for normal chromosome
segregation as well as the initiation of sporulation in Bacillus is. .1. Bacteriol. 176, 5320-
90994).
Jarboc, J .S., Johnson, K.R., Choi, Y., Lonser, R.R., Park, J.K. Expression of interleukin-] 3
or (12 in glioblastoma multiforme: Implications for targeted therapies. Cancer Res. 67,
7983—7986 (2007).
Jemal, A., Siege], R., Ward, E., Hao, Y., Xu, J., Thun, MJ. Cancer statistics, 2009. CA
Cancer J. Clin. 59, 225—49 (2009).
Juillerat-Jeanneret, L. The targeted delivery of cancer drugs across the blood-brain barrier:
chemical modifications of drugs or drug-nanoparticles? Drug Dlscov. Today 13, 1099-1106
Khalil, AM. et al. Many human large intergenic noncoding RNAs associate with chromatin-
modifying complexes and affect gene expression. Proc. Natl. Acad. Sci. U S A. 106, 11667-
72 .
Kota, J. at al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver
cancer model. Cell 137, [005-17 (2009).
Kreuter, J., Alyautdin, R.N., Kharkevich, D.A., Ivanov, A.A. Passage of peptides through the
blood—brain barrier with colloidal polymer les articles), Brain Res. 674, 171—174
(1995).
Kreuter, J., Petrov, V.E., Kharkevich, D.A., Alyautdin, R.N. Influence of the type of
surfactant 0n the analgesic effects induced by the peptide dalargin after its delivery across the
blood brain barrier using surfactant-coated nanoparticles, J. Control. Release 49, 81—87
(1997).
Kreuter, J. rticulate systems for brain delivery of drugs. Adv. Drug Deliv. Rev. 47,
65 81 (2001).
Kreuter, J., Shamenkov, D., Petrov, V., Ramge, P., Cychutek, K., Koch-Brandt, C.,
Alyautdin, R. Apolipoprotein-mediated transport of nanoparticle— bound drugs across the
blood brain r, J. Drug Target. 10, 317 325 (2002).
WO 88250 2012/002950
Kreutcr, 1., Ramge, P., Pctrov, V., Hamm, S., Gclpcrina, S.E., Engelhardt, B., Alyautdin, R.,
von Bn'esen, H., Begley, DJ. Direct ce that polysorbate—SO-coated
poly(butylcyanoacrylate) rticles deliver drugs to the CNS via specific mechanisms
requiring prior binding of drug to the nanoparticles, Pharm. Res. 20, 409—416 (2003).
Kreutcr, J., Gelpen'na, S. Use of nanoparticles for cerebral cancer. Tmnori 94, 271—277
(2008).
Kroll, R.A., Neuwelt, E.A. Outwitting the blood-brain r for therapeutic purposes:
osmotic opening and other means. Neurosurgeiy 42, 1083-99 (1998).
Kusuhara, H., Sugiyama, Y. (2005) Active efflux across the blood-brain barrier: role of the
solute carrier family. NeuroRx 2, 73-85 (2005).
Lambom, K.R. et al. Progression-free survival: an important end point in evaluating therapy
for recurrent high-grade gliomas. Neuro Oncol. 10. 162-70 (2008).
Laquintana, V., Trapani, A., Dcnora, N., Wang, F., Gallo, J.M., Trapani, G. New strategies to
deliver ncer drugs to brain tumors. Expert Opin. Drug Deliv. 6, 1017—1032 .
Loscher, W., and Potschka, H. Role of drug efflux orters in the brain for drug
disposition and treatment of brain diseases. Prog. Neurobiol. 76, 22-76 (2005).
Louis, D. N. et al. The 2007 WHO classification of tumours of the central nervous system.
Acta Neuropathol. 114, 97—109 (2007).
MacDiarmid, J.A. et al. Bacterially derived 400 nm particles for encapsulation and cancer
cell targeting of chemotherapeutics. Cancer Cell 11, 431—445 (2007).
MacDiamtid, J.A., Madrid-Weiss, J., Amaro-Mugridgc, N.B., ps, L. & Brahmbhatt, H.
Bacterially-derived nanocells for tumor-targeted delivery of chemotherapeutics and cell cycle
inhibitors. Cell Cycle 6, 2099—2105 (2007).
MacDiarmid, J.A. et al. Sequential treatment of drug-resistant tumors with ed minicells
containing siRNA or a cytotoxic drug. Nat. Biotechnol. 27, 643-651 (2009).
Moghimi, S.M., , A.C., Murray, J.C. dicine: current status and future
prospects. FASEB J. 19, 3] 1—330 (2005).
W0 2013/088250 PCT/IB201 2/002950
Morrison, P.F., Laske, D.W., Bobo, H., Oldfield, E.H., Dedriek, R.L. High-flow
microinfusion: tissue penetration and pharmacodynamics. Am. J. Physiol. 266, R292—305
(1994).
Nicolazzo, J .A., Katneni, K. Drug transport across the blood-brain barrier and the impact of
breast cancer resistance protein (ABCGZ). Curr. Top. in Med. Chem. 9, 130-147 (2009).
Nieth, C., et a]. Modulation of the cal multidmg resistance (MDR) phenotype by RNA
interference (RNAi). FEBS Lett. 545, 144-50 (2003).
Oh, Y.K., Park, T.G. siRNA ry systems for cancer treatment. Adv. Drug Deliv. Rev. 61,
850-62 (2009).
Okada, Y., Wachi, M., Hirata, A., Suzuki, K., Nagai, K., Matsuhashi, M. Cytoplasmic axial
filaments in ichia coli cells: possible functiOn in the ism of chromosome
segregation and cell division. J. Bacteriol. 176, 917-22 (1994).
Okada, H., et al. Expression of glioma-associated antigens in pediatric brain stem and non-
brain stem gliomas. J. Neurooncol. 88, 245—250 (2008).
Oritz-Zapater et a]. Key contribution of CPEB4-mediated translational control to cancer
progression. Nature ne, doi: 10.1038/nm.2540 (published e December 4, 201 l).
ri, D., r, J.L., Herring, J.M., Yoneda, T., Weil, R.J., Stark, A.M., et a]. Her-2
overexpression increases the metastatic outgrowth of breast cancer cells in the brain. Cancer
Res. 67, 4190—98 (2007).
Pardridge, W.M. Molecular biology of the blood-brain barrier. Mo]. Biotechnol. 30, 57-70
(2005).
dge, W.M. Drug targeting to the brain. Pharm. Res. 9, 1733-1744 (2007).
Pardridge, W.M. Blood-brain r delivery. Drug Discov. Today 12, 54—61 (2007).
Pardridge, W.M. Biopharmaceutical drug targeting to the brain. J. Drug Target. 18, 157-167
(2010).
Pardridge, W.M. Drug transport in brain via the cerebrospinal fluid. Fluids Barriers CNS 8,
1-4 (201 1).
PCTfl82012/002950
Petri, B., Bootz, A., Khalansky, A., Hekmatara, T., Muller, R., Uh], R., et a]. Chemotherapy
of brain tumour using doxorubicin bound to surfactant-coated poly( butyl cyanoacrylate)
nanoparticles: revisiting the role of surfactants. J. Control. Release 117, 51-58 (2007).
Rainov, N.G., Koch, S., Scna-Estevcs, M. & Bcrens, ME. Characterization of a canine
glioma cell line as related to established experimental brain tumor models. J. Neuropathol.
Exp. Neurol. 59, 607—613 (2000).
Raskin, D.M. de Boer, P.A. MinDE-dependent pole-to-pole oscillation of division inhibitor
MinC in Escherichia coli. J. Bacteriol. 181, 6419—6424 (1999).
Reardon, D.A. et a]. Phase II trial of murine (131)1-labeled antitenascin monoclonal dy
81C6 administered into surgically created resection cavities of patients with newly diagnosed
malignant gliomas. J. C/I'n. Oncol. 20, 1389-97 (2002).
Re, F., nica, l., Zena, C., Sesana, S., Gregori, M., Rigolio, R., La Perla, B., a,
F., i, G., Cagnotto, A., Salmona, M, Masserini, M, Sancini, G. Funetionalization of
Iiposomes with erived peptides at different density affects cellular uptake and drug
transport across a blood-brain barrier model. Nanomedicine 7, 551-559 (2011)..
Reeve, J.N., Cornctt, J.B. Bacteriophage SPOl-induccd macromolecular sis in
minicells llus subtilis. J. Virol. 15, 6 (1975).
Rice, S.L., Roney, C.A., Daumar, R, Lewis, 1.8. The next generation of positron emission
tomography radiophamiaceuticals in oncology. Semin. Nucl. Med. 4|, 265-282 (201 l).
Sabat, R. et a]. Biology ofinterleukin-IO. Ciao/tine Growth Factor Rev. 21, 331-344 (2010).
Sarin, H., Kanevsky, A.S., Wu, H, et a]. ive aseular delivery of nanoparticles
across the brain tumor barrier into malignant glioma cells. J. Trans/. Med. 6, 80 (2008).
el, A.H. P-glycoprotein, a gatekeeper in the blood—brain barrier. Adv. Drug Del. Rev.
36, 179-194 (1999).
Schinkel, A.H., Jonker, J .W. Mammalian drug efflux orters of the ATP binding cassette
(ABC) family: an overview. Adv. Drug Del. Rev. 55, 3-29 (2003).
Sioud, M. Therapeutic siRNAs. Trends Pharmacol. Sci. 25, 22-8 (2004).
2012/002950
Smith, .18. et a]. PTEN mutation, EGFR cation, and outcome in patients with
anaplastic ytoma and astoma multiforme. J. Natl. Cancer Inst. 93, 1246—1256
(2001‘).
Steinigcr, S.C., Krcuter, J., Khalansky, A.S., Skidan, l.N., Bobruskin, AL, et a].
Chemotherapy of glioblastoma in rats using doxorubicin-loaded nan0particles. Int. J. Cancer
109, 759-767 (2004).
er, H.J., Schmitt, M., Willems, A., Bernhard, H., Harbeck, N., Heinemann, V. Ratio
of trastuzumab levels in serum and cerebrospinal fluid is altered in HERZ-positive breast
cancer patients with brain metastases and impairment of blood—brain barrier. Anticancer
Drugs 18, 23—28 .
Stewart, LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-
analysis of individual patient data from 12 randomised trials. Lancet 359, 1011-18 (2002).
Stewart, PS. and D’Ari, R. Genetic and morphological characterization of an Escherichia
coli chromosome segregation mutant. J. Bacteriol. 174, 4513-6 (1992).
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoom MJ, et a].
Radiotherapy plus concomitant and adjuvant temozolomide for astoma. N. Engl. J.
Med. 352, 6 (2005).
Sun, H. et a]. (2003) Drug efflux transporters in the CNS. Adv. Drug Del. Rev. 55, 83-105
(2003).
Takeshita, F., et (1!. Systemic delivery of synthetic NA-l6 inhibits the growth of
metastatic prostate tumors via downregulation of multiple cell-cycle genes. M0]. Ther. 18,
181-7 (2010).
Weber, F.W. Local convection enhanced delivery of IL4-Pseudomonas exotoxin (NBI-3001)
for treatment of patients with recurrent malignant glioma. Acta Neurochir. Suppl. 88, 93-103
(2003).
Wisse, E., Jacobs, F., Topal, B., Frederik, P., De Geest, B. The size of endothelial fenestrae in
human liver sinusoids: implications for hepatoeyte-direeted gene transfer. Gene Ther. 15,
1193-1 199 (2008).
PCT/132012/002950
Wong, E.T. et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto
phase 11 clinical . J. Clin. Oncol. 17, 2572—2578 (1999).
Wrenseh, M., Minn, Y., Chew, T., Bondy, M., Berger, M.S. Epidemiology of primary brain
tumors: current concepts and review of the literature. New-0. Oncol. 4, 278-299 (2002).
Wykosky, J., Gibo, D.M., Stanton, 0, Debinski, W. Interleukin—l3 receptor 0. 2, EphA2, and
Fos-related antigen 1 as molecular denominators of high-grade astrocytomas and specific
targets for combinatorial therapy. Clz'n Cancer Res. 14, 199 208 (2008).
Xin, H., Jiang, X., Gu, J., Sha, X., Chen, L, Law, K., et al. Angiopep-conjugated poly(—
ethylene g1ycol)-co-poly(epsilon-caprolaetone) nanoparticles as dual targeting drug ry
system for brain glioma. Biomatert'als 32, 4293-305 (2011).
Yagiie, E., et 0/. Complete reversal of multidrug resistance by stable expression of small
interfering RNAs targeting MDR]. Gene Ther. ll, 1 170-4 (2004).
Yeshimasu, T, Sakurai, T., Oura, S., Hirai, 1., , H., Kokawa, Y., et al. Increased
expression of integrin alpha3beta1 in highly brain metastatic ne of a human non-small
cell lung cancer cell line. Cancer Sci. 95, 142—48 (2004).
Zensi, A., Begley, D., is, C., Legros, C., Mihoreanu, L., et al. Albumin nanoparticles
targeted with Apo E enter the CNS by ytosis and are delivered to es. J. Control.
Release 137, 78-86 (2009).
Zhang, Y., Pardridge, W.M. Conjugation of brain-derived neurotrophic factor to a blood-
brain barrier drug targeting system enables rotection in regional brain ischemia
following intravenous injection of the neurotrophin. Brain Res. 889, 49-56 (2001).
Claims (28)
1. Use of a ition in the manufacture of a medicament for ng a brain tumor, wherein the ition comprises a plurality of intact, bacterially derived minicells, and wherein: (A) each minicell of the plurality (i) comprises an antibody that specifically recognizes a tumor cell antigen and (ii) encompasses an anti-neoplastic agent; and (B) the brain tumor has blood vessels with fenestrations in its walls through which the minicells can extravasate passively.
2. The use of claim 1, wherein the anti-neoplastic agent is a radionuclide.
3. The use of claim 2, wherein the radionuclide is selected from yttrium-90, technetium-99m, iodine-123, iodine-131, rubidium-82, thallium-201, gallium-67, fluorine-18, xenon-133, and indium-111.
4. The use of claim 2 or claim 3, wherein the radionuclide is attached to a protein or a carbohydrate on a surface of the minicells.
5. The use of claim 4, wherein the radionuclide is attached to a bispecific antibody that is associated with the surface of the lls.
6. The use of any one of claims 2 to 5, wherein a eutically effective amount of said composition comprises about 30 Gy to about 100 Gy radioactivity.
7. The use of claim 1, wherein the anti-neoplastic agent is a chemotherapy drug.
8. The use of claim 7, wherein the chemotherapy drug has a lar weight of more than about 400 s. 7748231_1 (GHMatters) P97227.NZ 16-May-16
9. The use of claim 7 or claim 8, wherein the chemotherapy drug has a LD50 that is lower than the ED50 of the chemotherapy drug for a targeted cancer.
10. The use of any one of claims 7 to 9, wherein a eutically effective amount of the composition ses at most about 1 mg of said herapy drug.
11. The use of claim 1, wherein the anti-neoplastic agent is a functional nucleic acid or a polynucleotide encoding a functional nucleic acid.
12. The use of claim 11, wherein the functional nucleic acid inhibits a gene that promotes tumor cell proliferation, angiogenesis or resistance to herapy and/or that inhibits apoptosis or cell cycle arrest.
13. The use of claim 11 or claim 12, wherein the functional nucleic acid is selected from siRNA, miRNA, shRNA, lincRNA, antisense RNA, or ribozyme.
14. The use of claim 1, wherein the anti-neoplastic agent is a polynucleotide encoding a gene that promotes apoptosis.
15. The use of any one of claims 1 to 14, wherein each minicell of the plurality comprises a ligand having a specificity to a non-phagocytic ian cell surface receptor.
16. The use of claim 15, wherein the receptor is a tumor cell antigen.
17. The use of any one of claims 1 to 16, wherein a therapeutically effective amount of the composition comprises at least about 108 minicells.
18. The use of claim 17, wherein the eutically effective amount of the composition comprises at least about 1010 minicells. 7748231_1 (GHMatters) P97227.NZ 16-May-16
19. The use of claim 17 or claim 18, wherein the therapeutically effective amount of the composition comprises less than about 10 EU free endotoxin.
20. The use of any one of claims 1 to 19, wherein a therapeutically effective amount of the ition comprises at most 1 parent bacterial cell per 108 lls.
21. The use of any one of claims 1 to 20, wherein the brain tumor is selected from the group consisting of glioblastoma, astrocytic tumor, oligodendroglial tumor, moma, craniopharyngioma, pituitary tumor, primary lymphoma of the brain, pineal gland tumor, primary germ cell tumor of the brain, and combinations thereof.
22. The use of claim 21, wherein the brain tumor is metastatic brain tumor.
23. The use of any one of claims 1 to 22, wherein the brain tumor is glioblastoma.
24. The use of any one of claims 1 to 23, wherein the tumor is stage II, III, or IV tumor.
25. The use of any one of claims 1 to 24, wherein the tumor is stage III or IV tumor.
26. The use of any one of claims 1 to 25, wherein angiogenesis has initiated in the tumor.
27. The use of any one of claims 1 to 26, wherein vascularization has initiated in the tumor.
28. The use of claim 1, substantially as hereinbefore described with reference to the examples and figures. 7748231_1 ters) P97227.NZ 16-May-16 W0 88250 PCT/
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ709680A NZ709680B2 (en) | 2011-12-13 | 2012-12-12 | Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161569907P | 2011-12-13 | 2011-12-13 | |
US61/569,907 | 2011-12-13 | ||
PCT/IB2012/002950 WO2013088250A1 (en) | 2011-12-13 | 2012-12-12 | Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ626187A NZ626187A (en) | 2016-06-24 |
NZ626187B2 true NZ626187B2 (en) | 2016-09-27 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11964021B2 (en) | Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors | |
Guimarães et al. | Nanoparticles for immune cytokine TRAIL-based cancer therapy | |
US10500277B2 (en) | Combination tumor treatment with drug-loaded, bispecific ligand-targeted minicells and interferon-gamma | |
US20230079745A1 (en) | Compositions comprising bacterially derived minicells and methods of using the same | |
US20220202950A1 (en) | Compositions comprising bacterially derived intact minicells for theranostic applications | |
Shen et al. | Combating cancer stem-like cell-derived resistance to anticancer protein by liposome-mediated acclimatization strategy | |
NZ626187B2 (en) | Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors | |
NZ709680B2 (en) | Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors | |
AU2020205040A1 (en) | Encapsulated glycolipid antigens for treatment of neoplastic diseases |